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The identification of drug treatments that are useful in diverse therapeutic settings is
a significant driving force in biomedical research [55], [68], [48]. Typical means for measuring
the efficacy of a drug for a given clinical application include protein-protein interactions,
cell death, mitochondrial respiration and cell growth as well as broader measurements of
absorption, distribution, metabolism, excretion and toxicity (ADMET), specifically related
the the drug or drugs being tested [85]. A wide array of methods are routinely employed
to perform these screens, from ligand binding assays [93] to high-throughput proteomics
[91]. One method that is currently underutilized in small-molecule drug screens and drug
discovery is high-throughput transcriptome sequencing, such as RNA-Seq. Although RNA-
Seq is routinely used to profile patterns of genetic changes following perturbations such as
drug treatment [99], it has not, to my knowledge, yet been used as the primary readout of
a drug screen.
RNA-seq has been used in addition to other biochemical assays as part of an in-
tegrated screening pipeline, as in [33], but not as the primary, stand-alone readout of the
screen. In contrast to the previously mentioned drug screen measurements, RNA-Seq is a
much more scalable technology. The primary impediment to making full use of this po-
tential scalability, however, is the price of sequencing, which, while continuing to decline,
remains prohibitively expensive for many applications. Performing large-scale drug screens
is one highly desirable application.
Ultimately, a drug screen encompasses multiple perturbations that have genome-
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wide effects on cellular networks. The lack of a genome-wide readout is, therefore, a short-
coming in that it represents a lack of potentially very valuable information. This lack is
understandable, however, as the cost of sequencing large screens, which must frequently
take into account multiple drug concentrations across several time points, is considerable.
As we progress in our ability to interrogate cellular networks at a systems level, however,
vital techniques such as large-scale drug screens stand to benefit from advances in network
biology. To do so, however, they will require genome-scale outputs.
One way to drive down the cost of multiplexing greater numbers of treatments into
a drug screen is to lower the depth at which an expression library is sequenced, thereby
allowing more samples to be sequenced in any given run. There has been considerable
interest in making increasingly multiplexed expression libraries to enable researchers to
perform increasingly complex and larger-scale sequencing experiments, particularly in the
field of single-cell RNA-Seq, where samples must necessarily be barcoded and pooled [37],
[40], [38]. A question that is central to this investigation is that of how little sequencing
depth is needed to reliably measure gene expression signatures. In this dissertation, I will
describe a method for transcriptome profiling at the relatively low depth of 500,000 to
2 million reads per sample that enables increased sample multiplicity and is amenable to
network biology methods. Because this methodology rests on the availability of appropriate
gene regulatory networks with which to interpret transcriptome library sequencing results,
I will devote some time to describing what those networks are and how they are inferred.
1.1 The Biological Importance of Gene Regulatory Networks
A gene regulatory network (GRN) is a conceptual framework for modelling and
characterizing complex interactions between diverse components of a biological system.
[100]. Gene regulatory networks are critically important to the field of systems biology,
as they serve as a roadmap for understanding developmental and regulatory biological
processes [102] and for predicting cellular responses to external stimuli [24]. Differential
gene expression forms the basis of studies that seek to reverse engineer GRNs. Global
patterns of differentially expressed genes form a higher-order structure called gene expression
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profiles (GEPs). Because different phenotypic states are associated with characteristic gene
expression profiles, these profiles can be used to characterize specific phenotypic states, such
as responses to experimental perturbations. In this way, one can characterize the effect of
a give perturbation on cellular phenotypes and compare different perturbations based on
the impact that each has on GEPs. Given a specific target GEP, one describing a drug
susceptible state, for instance, drugs or other small molecules can even be screened for their
ability to induce that profile.
1.2 Inferring Gene Regulatory Networks
In any differential gene expression dataset, statistical associations such as coexpres-
sion or co-repression between various genes are sought to identify those genes that may have
relevant regulatory interactions. Although coexpression cannot unambiguously disentangle
cause from effect, nor differentiate direct from indirect interactions, either type of interac-
tion contains potentially useful information. Sets of genes that are differentially expressed
or repressed following a given perturbation may form functional modules that describe key
biological processes, such as cell cycle arrest or apoptosis, either of which are important
therapeutic target outcomes for a number of pathological conditions [21], [27], [82]. Gene
expression profiles can also be integrated with data from other sources, from tandem mass
spectrometry (MS-MS) and protein-protein interaction (PPI) inference algorithms to help
identify candidate physical interactions that can be validated biochemically.
1.2.1 Coexpression
Coexpression is arguably the simplest way to screen for potential genetic interac-
tions. Although many methods for generating coexpression-based networks have been pro-
posed, they all essentially follow the same two-step approach. Coexpression is measured in
the first step, with each pair of genes being assigned a similarity score, with the exact nature
of this score varying by method. The second step consists of setting a significance threshold
and connecting all genes with similarity values higher than the threshold by edges in the
resulting coexpression graph, an example of which can be seen in 1.1, from [94]. Common
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Figure 1.1: A coexpression network built around the SBP-box Gene in Arabidopsis. Wang,
et al., 2009.
measures for scoring gene expression similarity include the Pearson correlation coefficient,
Spearman rank correlation, euclidean distance, partial correlation [92], regression [67] and
more recently, mutual information. Each method for measuring coexpression brings its own
strengths and weaknesses to the analysis. The Pearson correlation coefficient is one of the
most widely-used means of estimating covariance in gene expression matrices. It takes on
values ranging from -1 to 1, where anything with an absolute value near one signifies a strong
correlation. Two drawbacks to the Pearson correlation coefficient are that it can be applied
to only linear relationships and that it is sensitive to outliers. Gene regulatory relationships
are rarely linear [34] and expression data is noisy and rife with outlying values. In contrast
to the Pearson coefficient, the Spearman rank correlation is computed on ranked values
and describes monotonic, rather than linear relationships. Euclidean distance, while simple
to implement, risks a high false positive rate from assigning significance to genes, whose
expression is consistently low, but are otherwise only weakly correlated or uncorrelated.
1.2.2 Bayesian Networks
A Bayesian network (BN) is another method for inferring and visualizing gene
regulatory relationships. As a directed acyclic graph (DAG), Bayesian networks express
the direction of each relationship (A operates on B, or vice versa) and does not allow loops
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Figure 1.2: A generic representation of a feedback loop, in which A activates B, which in
turn activates A. Source: Wikipedia.
in the network, which allows for efficient inference algorithms [63]. The expression of each
gene in a BN is represented as a conditional probability, depending on other genes in the
dataset. Formally, for a pair of genes A and B,
P (A|B) = P (B|A)P (A)
P (B) , (1.1)
where P(A) and P(B) are the marginal probabilities of A and B, P(A | B) is the conditional
probability, or that of observing A given that B is true and finally, P(B | A) is the probability
of observing B given that A is true.
Where biological systems do contain feedback loops, acyclic graphs do not serve as
their best representation. One means for overcoming this limitation has been to incorporate
time series data into Bayesian inference algorithms. The resulting networks are called
dynamic Bayesian networks and are better able to recapitulate biological network features,
such as feedback loops (Fig. 1.2) [7]. One drawback to using them, however, is that they
are not simple to implement, as they require many input parameters, which often require
machine learning methods to acquire. Although the requirement for many parameters can
make dynamic Bayesian networks difficult and computationally expensive to implement for
complete networks, they frequently find use in modelling sub-networks.
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1.2.3 Mutual Information Networks
More recently, information theoretic approaches have been applied to inferring bio-
logical networks. Mutual information (MI) has emerged as a robust way to measure indirect,
non-linear and non-monotonic relationships. Formally, the mutual information between two






p(x, y)log p(x, y)
p(x)p(y) , (1.2)
where p(x,y) is the probability of both X and Y being in the same state (their joint probabil-
ity), and p(x) and p(y) are the probabilities of either one being in said state (their marginal
probabilities). Intuitively, this ratio represents how much the knowledge of the state of one
of those variables reduces the uncertainty concerning the state of the other variable. At
the two extremes, this means that if X and Y are completely independent, then knowing X
provides no information concerning Y and vice versa, while if one is entirely deterministic of
the other, then knowing one implies knowing the state of the other completely. By operat-
ing under the assumption of complete independence between two genes, mutual information
then seeks to measure their inherent dependence. Formally, this means that I(X;Y) = 0 if
and only if X and Y are completely independent of each other. This is easy to see in the
case of complete independence, where p(x,y) = p(x)p(y). In that case,
log
p(x, y)
p(x)p(y) = log1 = 0. (1.3)
One potential disadvantage of using mutual information is the reliance on a large number
of input samples. The large sample number requirement for MI calculation occurs because
of the need to estimate the joint probability distribution of the expression of all gene pairs.
Additionally, the estimation of higher-order interactions can lead to spurious detection of
sophisticated non-linear relationships that are not biologically meaningful. Despite these
drawbacks, MI has proven to be a useful and robust method for inferring GRNs that has
been meeting with success in the field [51], [4].
The Califano lab has developed an MI-based algorithm called the Algorithm for
the Reconstruction of Accurate Networks (ARACNe) [56] to infer GRNs and in particular,
the interactions between TFs and their transcriptional targets. Because gene expression is
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regulated by TFs and their cofactors, which are themselves gene products, ARACNe rests
on the assumption that statistical associations between gene mRNA abundances should be
informative of, although not directly proportional to, protein activity. ARACNe works by
estimating the MI for interactions between all TF-target pairs (edges in a graph), setting an
MI threshold and applying the data processing inequality (DPI) to prune edges. The DPI
assumes that for any two genes that interact only through a third gene, the smallest MI
value for any of the three possible interactions must come from an indirect interaction, which
can be left aside in the search for direct TF-target interactions. Targets of TFs are then
identified as genes, that share high MI with the expression of a TF. Sets of targets that are
coordinately associated with a given TF are assumed to belong to the regulatory program of
that TF. These sets of TF-specific targets are known as regulons. This description is meant
to serve more as a description of the theory underpinning ARACNe, than as a mechanistic
explanation of how it works. ARACNe will be described in greater mechanistic detail in the
methods section, in Chapter Two. Because the networks built by ARACNe provide details
of which genes are targets of given TFs for specific cellular contexts, a natural extension of
this research was to use target mRNA abundances as a means of reporting on TF activity.
Where the targets of a certain TF are observed to be differentially expressed, one can
assume that the TF governing the expression of those targets is differentially active. This
is important because TFs are key drivers of cellular phenotypes and although alterations
affecting them are implicated in a number of disorders [25], [43], these changes frequently
occur post-translationally [26], [88], [45] and are therefore not directly captured in expression
data. Transcript abundances of a TF-specific regulon can fill this knowledge gap, as they
provide a direct link between target expression and TF activity.
A key feature of ARACNe-inferred networks is that they can be interrogated to find
the TFs, whose regulon enrichment patterns are indicative of specific molecular phenotypes.
The TFs responsible for the enriched regulons then theoretically describe the minimum set
of TFs required to achieve that phenotype.
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1.3 Applications of Gene Regulatory Networks
Simply being able to infer a GRN is not an end in and of itself. The utility of
these networks lies in being able to facilitate solutions for diverse biological and biomedical
questions.
1.3.1 Mapping the Causality of Genetic Interactions
The observation of how mRNA abundances change in response to experimental
perturbations, or simply over the course of time and development, provide information on
potential regulatory relationships between genes. As has been described in the sections
concerning how networks are inferred, these shifting expression patterns can be used to
determine which gene sets describe specific phenotypes or are used in certain biological
pathways.
1.3.2 Gene Regulatory Networks as Diagnostic Tools
Recently, the idea of using GRNs as diagnostic or prognostic tools has gained in-
creasing traction [15], [8], [11], [20]. This is a particularly attractive application for complex
disorders like cancer, which are represented by sets of interacting genes and their related
pathways, rather than by individual genes [35]. In this case, rather than relying on a small
number of defined genes, the network, or more likely a clinically relevant sub-network, would
serve as a biomarker for the condition. Ideally, network-based biomarkers would outper-
form their individual gene counterparts by being better able to account for the interaction
structure between the genes in the network. The need to consider systems-level interaction
changes is a feature not only of cancer, but of complex disorders in general, suggesting that
we can expect to see GRNs increasingly applied as diagnostic and prognostic tools in these
contexts as well. Nonetheless, developing accurate network-based biomarkers for complex
disorders remains a challenging task. Of the numerous obstacles to achieving this goal, two
of the most immediate are the need for large datasets covering multiple experimental con-
ditions and the cost of obtaining these datasets. The Califano lab has lately been pursuing
an interesting idea that may ease the acquisition of these datasets by lowering the amount
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of per-sample sequencing needed for analysis. Because the transcripts that are sequenced in
any RNA-Seq run are the transcriptional targets of active transcription factors, we reasoned
that the activity of these factors could be inferred from the differnetial expression of their
targets, an idea that will be discussed in greater detail in the following section.
1.3.3 Transcription Factors as Therapeutic Targets
Because of the role that transcription factors play in regulating cell responses, they
make desirable therapeutic targets. However, transcription factors are considerably chal-
lenging to operate on directly for a number of reasons [28]. First, they bind DNA, which
is negatively charged. This means that TFs tend to carry a positive charge, necessitating
that any molecule designed to bind to them carry a negative charge. Since the cell mem-
brane functions as a selective barrier to charged molecules, simply getting these theoretical
TF-targeting molecules into the cell presents one challenge. Second, TFs do not typically
bind small, distinct ligands. Kinases, for instance, bind ATP, so most of the drugs that
target kinases inhibit them by binding to their ATP binding pocket better than ATP can.
Metabolic enzymes typically bind small molecule metabolites, and can be interfered with
by making drugs that look like their metabolite of interest. Without a well-defined small
molecule interaction surface, drug makers are left to deal with the much greater interaction
surfaces that TFs use to interact with DNA and with multiple co-factors. Targeting such
a comparatively large interaction surface would necessitate designing similarly large drugs,
which would be mechanically hindered from accessing the cell’s interior. The fact that TFs
generally act in complex with other proteins presents yet another challenge to targeting
them directly. A final challenge in targeting TFs is in designing efficient, high-throughput
screening assays for molecules that can target them. To look for kinase inhibitors, for exam-
ple, one can design an assay that looks for ATP hydrolysis. Transcription factors lack any
such straightforward and uniform enzymatic activity, necessitating more complex, expen-
sive and lower-throughput assays. RNA interference-based strategies have been proposed
to target TF expression in disease contexts, but effectively delivering these therapies in
a clinical setting remains problematic [98], [42], [19]. A screen that allows us to control
them based on how drugs alter their activity may be the most actionable strategy possible.
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Figure 1.3: Transcription factor pleiotropy: each TF regulates the expression of multiple
downstream targets (gi).
To this end, the Califano lab has pioneered the Virtual Inference of Protein-activity by
Enriched Regulon analysis (VIPER) algorithm, which estimates TF activity from regulon
transcript abundances given a cell context-specific ARACNe-inferred network (Alvarez, et
al., under review).
1.4 Inferring Transcription Factor Activity From Gene Reg-
ulatory Networks
Transcription factors operate pleiotropically, in that each TF regulates the expres-
sion of multiple transcriptional targets, as shown in Fig. 1.3. Because of this pleiotropy,
we hypothesized that TF activity could be estimated from a relatively low number of reads
per transcriptional target, as long as there were multiple targets from which to sample.
This would allow the possibility, at least in theory, of coupling the reduction in sequencing
10
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Figure 1.4: VIPER retains strong positive correlation to a larger network across a range of
read depths. Alvarez, 2012.
depth per sample to an increase in the multiplexing of samples in an expression library.
Because each TF, on whose activity VIPER reports, is inferred from multiple transcripts,
we hypothesized that fewer total reads would be needed per experiment, to successfully run
VIPER. One of the difficulties in working with low-depth RNA-Seq data is that the strength
of a gene expression signature decays rapidly with reduced depth [87]. To test VIPER’s
sensitivity to sequencing depth, we interrogated 100 breast cancer RNA-Seq experiments
from the TCGA database. Reads from each experiment were sampled, starting at 30 mil-
lion (30M) and going down to only 10,000. Gene expression profiles and VIPER-inferred
TF activity profiles were computed at each sampling and the correlation to the full 30M
reads was measured. Figure 1.4 shows the average correlation between each down-sampling
experiment and the corresponding sample at the full 30M reads. This demonstrates that al-
though the gene expression signatures are quickly degraded, the VIPER-inferred TF activity
signatures remain highly conserved across a range of sequencing depths, only significantly
falling off after approximately 500,000 reads. This suggested that VIPER could accurately
infer network characteristics at even very low read depths, thereby increasing the number
experiments that could be multiplexed into a single sequencing run.
In another early test of VIPER’s efficacy, data from a single-cell glioblastoma
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(GBM) RNA-Seq study were used to compare the relationship between the detection of
TF expression and inferred activity. The TFs identified in the study could be classified into
three groups; those which were detected at the level of mRNA in all samples, those which
were detected in some samples and those, whose mRNA transcripts were not detected in
any of the samples. As can be seen in Fig 1.5, VIPER was able to infer the relative activity
of TFs, even when their coding mRNA fell below the detection limit.
Efforts have been made in the past to increase the number of transcription libraries
that can be sequenced simultaneously or to in other ways reduce the number of needed
inputs for network reconstruction. In the former case, transcriptome library preparation
methods have been developed that make use of molecular barcodes to maintain separation
between pooled samples [37], [77], [47]. In the latter case, initiatives like the LINCS program
have sought to find a minimal set of genes, whose differential expression is informative of
diverse cellular states. These ’reduced representation’ gene expression profiles, however,
have proven to be ill-suited for network approaches, which tend to rely on a greater number
of inputs. Despite the number of barcoding and pooling strategies available for building
multiplexed transcription libraries, all of them rest on the assumption that a high sequencing
depth of roughly 30M reads will be needed for network deconvolution. Many studies that
would make use of highly multiplexed library sequencing would benefit most from being able
to sequence a very large number of samples, covering multiple experimental conditions, such
as drug screens, in which it is important to sample across multiple time points and drug
concentrations. Performing this level of sequencing at high depth remains prohibitively
expensive.
1.5 Pooled Library Amplification for Transcriptome Expres-
sion Sequencing
Here, I present a method for preparing transcriptome libraries for reduced depth
sequencing and network analysis. I call this method Pooled Library Amplification for Tran-
scriptome Expression Sequencing, or PLATE-Seq. The fundamental point of PLATE-Seq
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Figure 1.5: VIPER detects TF activity even when the expression for that TF could not be
detected. Columns are samples, rows are TFs. Red indicates increased expression or activity,
blue indicates decreased expression or activity and gray indicates that the expression of the
gene in question was not detected. Alvarez, 2013.
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operate on gene expression profiles. PLATE-Seq makes use of both sample-specific and
molecular barcoding strategies and incorporates high-throughput liquid handling robotics
to dramatically drive down the per-sample cost of expression library preparation. The gene
expression profile (GEP) specificity of PLATE-Seq stems from the fact that this method does
not sequence over the entire gene body, but rather adopts a poly-A tail capture technique.
It furthermore relies on reduced PCR amplification to keep captured mRNA abundances
closer to the linear expression range, in contrast to established techniques such as Illumina’s
TruSeq protocol, in which amplification bias is a serious concern. While these factors make
PLATE-Seq inappropriate for studies seeking out mutations in specific genes, or alterna-
tive splicing events, it makes for a highly efficient gene expression profiling technique with




The PLATE-Seq protocol is designed to reduce the overall number of steps involved
in library preparation, both as part of its goal of reducing the cost of library preparation
and to minimize the amount of manual labor involved, thereby limiting the opportunity for
human error and the considerable variations in experimental inputs that stem from sources
such as pipetting error and minor variations in incubation lengths and interstep temporal
variations.
Briefly, the protocol consists of seeding a 96-well plate with cells, administering
experimental treatments and lysing the cells at the appropriate time. mRNA is isolated
from the cell lysates, reverse transcribed with bar-coded oligo(dT) primers and pooled. All
steps prior to pooling are performed on a liquid handling robot to reduce the occurrence
of batch effects. Second strand synthesis is performed on the pool and if desired, using a
second set of bar-coded random primers for future correction of PCR bias. The library is
then split into several dilutions and amplified with 12 or fewer PCR cycles. The dilution that
results in the minimal amount of library needed for loading into the sequencer is selected
for sequencing, as this is the library, whose transcript abundances are most likely to be
closest to the linear range of expression. Sequencing is carried out in the Illumina NextSeq







Figure 2.1: Outline of the PLATE-Seq experimental workflow
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2.1 Detailed Steps of the PLATE-Seq Protocol
2.1.1 Tissue Culture
Currently, the protocol begins with seeding cells into a 96-well plate. Efforts are
underway to adapt the protocol to the higher throughput setting of 384-well plates. Cells
must be seeded at a concentration that allows them to grow for enough time to recover from
the shock of having been split and seeded, which may vary considerably for the cell type in
question. As of this writing, we have had steady success plating a variety of immortalized
cancer cell lines, but have experienced greater challenges with cells of nervous tissue origin.
Initial cell density must also take into account the amount of time needed to complete
the experiment without overcrowding, which is a condition associated with genetic and
biochemical changes that can be challenging to distinguish from the changes induced by
experimental treatments [96], [57], [30]. These parameters must generally be determined
empirically.
2.1.2 mRNA Isolation
The first step in RNA isolation is to lyse the cells containing the RNA of interest
without causing undue RNA degradation. The steps of PLATE-Seq, from mRNA isolation
until pooling of the samples, are fully automated, using a robotic protocol. The automation
facility at the Columbia University Medical Campus uses a Hamilton MicroLab STAR liquid
handling robot, which was used for all the automated experiments detailed herein. Lysis
is performed using a buffer consisting of 99% TCL (Qiagen) and 1% beta-mercaptoethanol
(βME). This buffer hypotonically lyses the cells, while the TCL, consisting predominantly
of guanidine thiocyanate, inhibits the action of RNAses present in the cellular lysates. The
minimal volume of lysis solution that was found to be needed to effectively lyse cells in the
96-well plate format was 30µL. Prior to lysis, cells were washed twice with PBS, to remove
the culture media. Cells incubated in the lysis buffer for 5 minutes, at room temperature
and the lysates were vigorously pipetted to ensure efficient cell lysis and cleared by gentle
pulse centrifugation prior to being transferred to an mRNA capture plate.
The mRNA capture plate is a 96-well plate, wherein the sides of each well are coated
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with plate-bound oligo(dT). The oligo(dT) efficiently anneals to the poly-A tails of the
mRNA molecules. The mRNA is eluted from these wells following the manufacturerâTMs
protocol and transferred to a fresh 96-well PCR plate, whereupon the ERCC spike-in con-
trols and bar-coded, Illumina adapter-linked primers are added. 1µL of a 1:100 dilution of
either of the two ERCC spike-in mixes are added to alternating wells in order to quantify
the amount of variation in mRNA yields between wells and to later assess for the occurrence
of cross-talk between wells. 3µL of 100µM bar-coded, adapter-linked primers are added.
The plate is then heated to 94C for 2 minutes to fragment the mRNA, thereby destroying
much secondary structure that may interfere with primer annealing and reducing the range
over which mRNA molecules in the library may vary. This is an important consideration
for PCR amplification, in which shorter molecules may out-compete longer ones for relative
abundance in the library, which reduces overall library complexity. One critical consider-
ation at this step is to transfer the freshly fragmented mRNA directly and immediately
to ice in order to allow the bar-coded primers to anneal to the poly-A tails of the mRNA
fragments faster than the mRNA can refold into secondary structures that would impede
primer annealing.
2.1.3 Reverse Transcription Library Pooling
Reverse transcription is then performed using Protoscript II reverse transcriptase
(NEB). Reverse transcription proceeds for 120 minutes at 42C, after which the reverse
transcriptase (RT) is heat inactivated for 20 minutes at 65C, to limit the possibility of
remaining active RT priming off of a bar-coded primer from one well annealed to a transcript
from a different well. TO further control for the incidence of cross-talk, remaining primer
is removed by digestion with ExoI for 1 hour following reverse transcription. Because ExoI
can also degrade the ssDNA of the library, it is inactivated with 20µL of a 1:1 mixture of 1M
NaOH and 0.5M EDTA for 15 minutes, after which samples are pooled together. Finally,
80µL of 12M HCL is added to neutralize solution. At this point, the samples from separate
wells are pooled together and can be treated as a single sample for all downstream steps.
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2.1.4 Concentration of Pooled Library
Due to constraints imposed by the robotic liquid handling system, the pooled volume
is larger than needed for the downstream steps. Although the first action post-pooling is to
clean the library of its ExoI neutralization buffer and concentrate it to a smaller volume, the
amount of hands-on time required to concentrate it from the 40mL that the robotics facility
delivers to the 15µL required for the rest of the protocol is significant without access to a
vacuum spinner capable of handling 50mL conical tubes. For this reason, only an aliquot
of the pooled library is concentrated, while the remainder is stored at -80C, in case more
is needed later, for example, in the case of having to repeat a sequencing run. As the cell
culture and liquid handling components of the protocol are also the most time-intensive,
having a reserve of pooled library serves as a practical safeguard against having to repeat an
experiment from the very beginning. Library concentration is performed on silica membrane
columns using the Zymo DNA Clean and Concentrate kit as per the manufacturer’s "ssDNA"
protocol. To further ward against contamination by residual primers, which can affect
library amplification efficiency, the pooled library is purified with Ampure XP beads at a
1:1 beads-to-library ratio (by volume) and eluted in 15.0µL of nuclease-free water.
2.1.5 Second Strand Synthesis
Second strand synthesis is performed using the large Klenow fragment, which has
exonuclease activity. The exonuclease activity helps to further limit cross talk by eliminating
any remaining well-specific primers that may have carried over through the prior steps.
1.0µL of a 10mM dNTP mix and 1.0µL of a 100µM random bar code primer mix are added
to the library, which is then incubated at 70C for 2 minutes and immediately transferred
to ice, to incubate for another 5 minutes. 2.0µL of Buffer 2 (NEB) and 1.0µL of DNA
polymerase I are then added to the library and second strand synthesis is allowed to proceed
by incubating the entire mixture at room temperature for 30 minutes. The resulting double-
stranded cDNA is purified with Ampure XP beads at a 1:1 ratio, to remove all residual
primers and finally eluted in 20µL of nuclease-free water.
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2.1.6 Amplification
Because of the reduced sequencing depth, it is critical to minimize PCR amplifica-
tion bias. For PCR amplification, three dilutions of the library are made; a 1:2.5 dilution
of the original solution and a 1:2 dilution of the 1:5 dilution. 2.5µL of the original library
and each dilution were mixed with 22.5µL of a PCR reaction mix for final library dilutions
of 1:10, 1:25 and 1:50. The libraries were amplified with 12 PCR cycles. The products were
purified twice with Ampure XP beads at a 1:1 ratio, eluted in 12.0µL of nuclease-free water
and aliquots were taken for quantification by qubit and analysis by Bioanalyzer.
2.1.7 Sequencing
Sequencing for PLATE-Seq experiments is performed by paired-end sequencing on
Illumina’s NextSeq 500 v2 (high throughput) platform. The NextSeq 500 is the current
model of Illumina’s reversible-terminator sequencing-by-synthesis (SBS) technology. Re-
versible termination refers to the use of dNTPs, modified to contain a fluorescently-labeled
terminator molecule, which inhibits further polymerization after incorporation into a grow-
ing strand. This prevents the addition of multiple nucleotides in a single sequencing round,
which would otherwise significantly increase the sequencing error rate. Sequencing is car-
ried out simultaneously on millions of template cDNA fragments bound to the surface of
the flow cell. The flow cell is coated with adapter sequences, which anneal to the template
cDNA molecules through complementary sequence binding. The initial input templates are
amplified to produce clonal template clusters, which are vital for quality control purposes.
The presence of both forward and reverse strands in the sequencing reaction provides a
check against sequencing artifacts. If one strand is found to have an odd sequence, then it
can be checked against its paired strand to confirm whether or not the complement contains
the same oddity. Clonal clusters also amplify the signal from each fluorescent dNTP used
in the sequencing reaction, as a single fluorescent label falls below the limit of sensitivity of
the deviceâTMs cameras. Following clonal amplification, the sequencing reaction proceeds
in cycles, with a single nucleotide added at each cycle. After the addition of each nucleotide,
an image is taken of the fluorescence pattern across the flow cell and the terminators on
each nucleotide are cleaved to allow incorporation of a new nucleotide in the subsequent
20
cycle. The incorporation of a single base per cycle allows the sequencing reaction to produce
a set of reads of uniform length. The reaction proceeds for a defined number of cycles, after
which the raw data is sent for primary read alignment and downstream processing.
2.2 Data Analysis
2.2.1 Sequence Alignment
The primary processing of the raw reads is a fully automated process, in which the
reads generated during sequencing are mapped to the appropriate genome using the STAR
Aligner [23]. The output of this process is a text file containing the gene counts for each
sample (bar code) in the library.
2.2.2 Normalization and Comparison of Gene Expression Profiles
Data normalization is first performed by variance stabilization of the raw counts
using DESeq2, an update of the well-established DESeq package [1], [54], [32]. The theory
behind DESeq and DESeq2 is that HTS experiments frequently suffer from a small sample
size, likely because the cost of performing sequencing at high depth restricts the number
of samples that can be sequenced. These small sample sizes lead to large uncertainties
of intragroup variance estimates and a resulting lack of statistical power. DESeq and
DESeq2 meet this challenge by modeling the dependence of the amount of variation, or the
dispersion, on the average expression strength across all samples. Dispersion refers to the
variability in counts between replicate treatments and proper estimation of this variation is
critical to accurately infer differential gene expression. DESeq2 makes the assumption that
genes of similar average expression strength will display similar dispersion. The algorithm
estimates dispersion by first estimating variability on a per-gene basis, then fitting these
estimates to a smooth curve to produce an accurate estimation of expected dispersion values
for each gene. It then shrinks the gene wise dispersion estimates towards the values of the
fit curve. These shrunken values are the final dispersion estimates. The strength of each
gene’s shrinkage factor depends on both how close true dispersion values are to the fit and
on the degrees of freedom in the dataset. The more samples there are, the less strong the
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effect of shrinkage becomes.
2.2.3 The VIPER Algorithm
The VIPER algorithm tests for the enrichment of TF-specific regulons in gene ex-
pression signatures (Alvarez, et al., in review). Regulon enrichment is computed through an
algorithm called the analytic rank-based enrichment analysis (aREA). aREA detects shifts
in regulon enrichment by comparing the positions of regulon genes to rank-sorted gene ex-
pression profiles and assigning to each regulon gene an enrichment score (ES). aREA first
computes the ES for regulon genes by rank-sorting them based on their absolute expression
fold change, invariant to the direction of their changes in expression. In this way, the genes
with the greatest changes in expression in the experimental condition are easily identified.
In the next step, the algorithm re-orders the list of differentially expressed genes, based on
the direction of regulation between the gene and its regulator. The results of these two
calculations are integrated and the contributions of each are weighted based on the results
of another part of the algorithm, called the Mode of Regulation (MoR). The MoR describes
the direction of interaction between a regulator and a target. It is based on the Spearman
correlation coefficient (SCC) between a regulator and the expression of a transcriptional
target, as computed from the dataset used to reverse engineer the network. Finally, aREA
calculates the statistical significance for each ES through comparison to a null model that
is generated either by a random uniform permutation of the samples or by a random uni-
form permutation of the genes in the dataset, should there be too few samples to generate
sufficient statistical power.
2.2.4 ARACNe
Because of the central role that ARACNe-inferred networks play in VIPER analysis
and in more generally in the current PLATE-Seq experimental pipeline, it is worth describ-
ing the mechanics of this algorithm in greater detail. ARACNe reverse engineers biological
networks in two steps. Broadly, it first estimates the pairwise mutual information between
all genes in a gene expression profile and filters these interactions based on a threshold MI,
I0, computed for a specific p-value, p0, in the null-hypothesis of two independent genes.
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This step is essentially equivalent to the Relevance Networks method [9], and, as such, suf-
fers from the same limitations. In particular, genes separated by one or more intermediaries
may be highly co-regulated without implying a direct physical interaction.
The second step in ARACNe is designed to account, at least in part, for the effects
of indirect regulation. In this step, ARACNe removes the majority of candidate indirect
interactions through an application of the data processing inequality (DPI) [18]. The DPI
argues that if two genes, g1 and g3, interact only through a third gene, g2, and no alternative
path exists between g1 and g3, then the information between g1 and g3 cannot be greater
than that which is estimated between either of the other two pairs. Formally,
I(g1, g3) ≤ min[I(g1, g2); I(g2, g3)]. (2.1)
The implication is that the smallest of the three MI values in a triplet implies an indirect
interaction. ARACNe examines each triplet set of interactions in which the MI for each
interaction is greater than I0 and culls the edge with the smallest value. Because each
triplet is analyzed independently of whether its edges were previously marked for removal
as part of another triplet, the network that ARACNe reconstructs is independent of the
order in which triplets are examined.
Given ARACNe’s focus on pairwise interaction, it is not well-suited to identifying
higher-order interactions between mutually independent genes, or those for which Ii, j < I0.
It would also fail to recover pairwise interactions, wherein the effect of a direct interaction
is cancelled out by indirect actions transmitted through other genes. However, such precise





The PLATE-Seq protocol has gone through several iterations to arrive in its current,
and still evolving, state. PLATE-Seq was originally proposed by Peter Sims as a potential
protocol to address one of Andrea Califano’s research goals. The Califano lab has grants
for several projects that require or would significantly benefit from considerable amounts of
sequencing. These include efforts to construct libraries of transcriptome-wide drug profiles
in multiple cellular contexts and using transcriptomics to search for master regulators of
individual drug response through testing multiple drug treatments against patient-derived
tumor tissue. It became my task to develop and test the protocol and to shephard it towards
something that could be used reliably at high scale.
All iterations of the PLATE-Seq protocol follow the essential steps involved in RNA
purification and library preparation. The key differences are early pooling and reduced
depth sequencing. The latter is only rendered useful thanks to network biology approaches
like the VIPER algorithm that boost the information we gain from low-depth sequencing
results by incorporating prior gene regulatory knowledge into the analysis.
Our goal was to able to perform PLATE-Seq on multiple 96-well plates. The plan is
to eventually adapt the protocol to 384-well plates to further increase the scale of the proce-
dure, but this will be a project for future lab members. We knew going in that developing a
reliable and replicable protocol for 96-well plates would be an already significant challenge.
Peter Sims and I developed a plan to develop the protocol in stages. After working out an
outline for the protocol, I would test each step in a single sample setting, looking for any
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weaknesses in each procedure that was to be performed. Specifically, we wanted to show
that we could efficiently purify mRNA while removing any rRNA and gDNA contamina-
tion. We needed to know the size range of the libraries that came from our protocol, to be
able to control the length distribution and we needed to know the minimal amount of PCR
amplification that we could use, to minimize PCR-induced length bias without sacrificing
library complexity.
After working out any bugs in the single-sample setting, I would then scale the
protocol up to a higher throughput setting of 48 wells. Although anything that works in
48 wells should work just as well in 96, we chose not to assume success and to scale the
procedure up to just half a plate first. Doing so would also reduce the reagent cost involved
in performing an experiment that may contain unforeseen bugs.
3.1 Testing Protocol on Single Samples
The first protocol involved single samples of total RNA, purified from MCF7 cels. I
performed mRNA purification from this starting material using a streptavidin-biotin pull-
down. Immediately following the mRNA capture and prior to the bead pull-down, I split
the sample into two aliquots, one of which would be treated with exonuclease I (exoI) and
the other of which would not, to determine whether or not digestion by exoI was needed
to remove biotinylated transcripts from streptavidin beads. In the first trials of the pro-
tocol, I captured mRNA by annealing biotin-conjugated oligo(dT) to the poly-A tails of
mRNA and performed reverse transcription using bar-coded and Illumina adapter-linked
random primers. I next used Zymogen’s RNA clean-up kit to remove DNA contamination,
following the manufacturer protocol. I then purified the captured mRNA with streptavidin,
incubating each sample on a rotisserie for one hour at 4 degrees. Second strand synthesis
was then performed using random hexamer barcodes and klenow(exo-) and the resulting
double-stranded libraries were then amplified with the Phusion DNA polymerase as in later
protocols.
Because the protocol at this point was in the very early stages of development, care
was taken to measure the output of every step. At each washing step (the the RNA clean-up
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Figure 3.1: A. Total RNA purification from MCF7 cells. The two prominent peaks show
rRNA. B. Results of bead pulldown and washing. PW = pre-wash, W1 = 1st wash, E =
eluate. Although the library concentration at these steps is still too small to see on the
bioanalyzer, the protocol steps effectively remove rRNA.
and after the bead pull-down), aliquots of the library were removed prior to the wash, after
a first wash and from the eluate, to assay for the presence of potential library components
in anything but the eluate.
Results at these stages were encouraging, showing peaks tracking to the expected
sizes for ribosomal RNA in the pre-wash samples only, following bead pull-down, as assayed
on the bioanalyzer. At this point in the protocol, the amount of unamplified library re-
mained below the limit of detection of the bioanalyzer, making an apparently blank trace
a potentially positive result (Fig 3.1).
At this stage, we knew that minimizing the degree of PCR amplification bias in the
libraries would be critical to success, but didn’t know how many cycles of PCR we should
use. To get an empirical feeling for how amplification affected the library, I split the double-
stranded, non-amplified library into five separate aliquots and amplified each aliquot with a
different number of cycles, covering several orders of magnitude of amplification. Initially,
I used 8, 12, 16, 20 and 30 PCR cycles. I assessed relative amplification and determined
library length by running each amplified aliquot through a 1.5% agarose gel. This first
attempt showed only a smear in both lanes of the 30 cycle samples, which I reasoned would
represent strong overamplification. I repeated this procedure and found a smear in only the
exoI+ lane at 16 cycles that ranged the length of the size ladder, with a denser bulge in
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the range of approximately 300bp - 600bp (Fig 3.2). No smear was visible in the exoI- lane.
This suggested that exoI was, in fact, needed to free biotinylated transcripts from beads
following purification. I controlled the library length by excising the smear approximately
between 230bp and 600bp and then measured library concentration by qPCR.
Buoyed by the results of the single-sample experiment, I adapted the protocol to the
higher-scale setting of one half of a 96-well plate. The first step was to optimize the number
of cells per well. Initially, I seeded 48 wells with 5,000 MCF7 cells per well, but was unable
to see evidence of a library in the gel following amplification. After discussing this results
with Peter, we decided that rather than expending resources on a blind gel purification and
qPCR, I would repeat the procedure, doubling the number of cells per well. This could later
be attenuated, but we needed a library that we could see, in order to track the progress of the
current protocol. I seeded 10,000 MCF7 cells per well in the following experiment. However,
bioanalyzer traces showed that the starting total RNA may have been heavily degraded
and the gel following the PCR showed smears that were heavily concentrated below 600bp,
further indicating that there were likely structural problems related to transcript quality
in this sample. I repeated the experiment, using more superaseIN in the lysis buffer, to
counter any unwanted RNA degradation. I amplified aliquots of the library using 12, 20
and 24 cycles of PCR, then gel purified and quantified the resulting libraries.
After convincing ourselves of the technical success of the 48 well trial, I performed
three trials using full 96-well plates. The first was a run of just the pre-sequencing steps,
the second was a full sequencing run performed to assay for cross-talk between wells and the
third was an experiment with drug treatments. In the first case, all steps appeared success-
ful, with the final result of a 20nM library; more than enough to be sent for sequencing. It
was at this point, that the idea came to load the wells of a plate in such a way that we could
assess the presence of any cross-talk between wells. I forget who thought of it first, but after
it was brought up, Peter and I decided that rather than send the library that I had just
built for sequencing, I would set up another run, this time with alternate wells seeded with
cells that could be separated by barcodes post-sequencing. For this experiment, I chose to
use two cell lines that had been given to me by the da Silva Lab. One was an MCF10A line



















shSTAT3 vector. since MCF10A cells normally express STAT3 at high levels, I would be
able to use STAT3 as a marker for cross talk by mapping bar-coded sequences to each well.
Unfortunately, I could only detect STAT3 in 28% of all samples in the library. I checked
STAT3 expression in each cell line and found that it was undetectable in both. The lesson
learned in this experiment was to validate all claims concerning reagents prior to using
them.
I repeated this experiment, alternating columns of a 96-well plate with unmodified
MCF7 cells and GFP-expressing MCF10A cells. I verified GFP expression by microscopy.
This showed that all bar codes were well-represented in the resulting library, that reads
mapping to the GFP vector were detected in 94% of the expected wells and that 99.96% of
the reads that uniquely mapped to GFP were associated with wells to which GFP+ cells
were added (Fig 3.3). The 0.04% of GFP reads mapping to other wells were traced to a
single bar code in a single well. This demonstrated a sufficiently high level of well-to-well
fidelity that we decided to design an experiment to further test the quality of information
that we could obtain through PLATE-Seq.
We next designed an experiment involving drug perturbations, to evaluate our abil-
ity to obtain clear and differentiable gene expression profiles and VIPER-inferred protein
activity profiles using PLATE-Seq, this being the primary motivation for developing the
technique. This experiment consisted of a set of seven drug treatments at two concentra-
tions and two points, with three biological replicates per treatment. For this version of the
protocol, Peter and I decided to add a phosphatase digestion step, following the exonuclease
digestion, which would strongly limit any residual action by reverse transcriptase, ruling
that out as a potential source of the cross-talk seen previously. The results of this experi-
ment showed that treatment replicates tended to be well-correlated, both at the level of gene
expression and of VIPER-inferred protein activity, as measured by the Pearson correlation
between either gene expression or protein activity signatures. A drawback to this analysis,
however, was that we did not see strong differences between signatures from diverse treat-
ments. While discussing ways to overcome this, we were approached by collaborators, who
were interested in the potential benefits of PLATE-Seq and in doing experiments with us,
while we developed the technique further. These experiments are discussed in the following
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Figure 3.3: GFP marker representation across the 96-well plate.
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chapter.
To complete the discussion of how I developed the PLATE-Seq protocol, I’ll end by
briefly mentioning the experiments that I carried out in parallel with those detailed in the
next chapter.
One interesting collaboration that was proposed to us by Dr. Serge Przedborski
involved adapting PLATE-Seq for use with motor neurons. The key challenge in this set
of experiments was the cell culture. Unlike immortalized cell lines, motor neurons require
significantly more space between cells in order to grow in a healthy manner and so cannot
be grown to confluency. The must also be cultured for a longer period of time than immor-
talized cells, which makes them more prone to culture phenomena such as the edge effect,
in which cells grown in the peripheral wells in a multiwell plate lose a greater proportion
of their culture media to evaporation, negatively impacting their health. These effects gave
me fewer cells to work with than in past experiments. This, in turn, caused me to use to
a greater number of PCR cycles when amplifying the library, which lead to critical loss
of library complexity due to amplification bias. It is important to note that at this stage
in protocol development, I was still heat fracturing mRNA to homogenize read lengths
prior to reverse transcription. Later versions of the PLATE-Seq protocol incorporated a
plate-based 3-prime mRNA capture, followed by first strand synthesis by priming directly
off of the poly-A tail, which significantly improved mRNA capture efficiency and library
complexity, as detailed in the Methods chapter. Although I am no longer involved in the
motor neuron project, it is my understanding that a much greater degree of success has
been found by employing the most current protocol.
In a further effort to reduce opportunities for cross-talk, I experimented with com-
paring the effects of treating wells with exoI and recombinant shrimp alkaline phosphatase
(rSAP), which removes the phosphate needed by RT to carry out its function, to heat-killing
RT by adding a 20-minute, 65C step at the end of the reverse transcription thermocycler
protocol. This experiment showed that heat killing RT was equivalent to the exoI + rSAP
digestion, which allowed us to save on reagent cost by excluding rSAP and limiting the
amount of exoI used in the protocol.
One strategy that we briefly pursued was the incorporation of a terminal transferase
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step into the protocol. Terminal transferase adds adenine nucleotides to the 3’ end of
ssDNA. Peter and I reasoned that this would reduce reagent costs and improve second strand
synthesis efficiency by allowing second strand priming to take place on a single sequence,
shared by all reads. Although this worked, we shortly afterwards came up with the idea of
using the oligo(dT)-coated plate for mRNA capture, followed by thermal fragmentation of
the mRNA molecules, which was both more efficient and less laborious, making it better-





In developing PLATE-Seq, our primary technical challenge has always been to
demonstrate that results obtained through PLATE-Seq and analyzed by VIPER are func-
tionally equivalent to those obtained through standard expression library preparation meth-
ods and high-depth sequencing. To this end, we have performed several comparative exper-
iments to test PLATE-Seq’s efficacy in various conditions.
4.2 Testing PLATE-Seq Results Against a Matched Dataset
of Previous Sequencing Results
As an early test of the PLATE-Seq method, we repeated a previous drug screen that
had been performed as part of a project involving neuroendocrine tumors. The previous
screen had been performed using the TruSeq expression library preparation method and
libraries from that project had been sequenced to a depth of 30M reads on the HiSeq 2000
(Illumina).
4.2.1 Experimental Set-Up
Two 96-well plates were seeded with 30,000 H-STS cells 16hrs prior to drug treat-
ment. To test both the reproducibility of PLATE-Seq samples and to get an estimate
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1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	  
A	   AZD8055	  -­‐	  20uM	   MK-­‐2206	  -­‐	  6.84uM	  
DMSO	   Empty	  
B	   AZD8055	  -­‐	  2uM	   MK-­‐2206	  -­‐	  0.684uM	  
C	   Belinostat	  -­‐	  0.0325uM	   Tiva<nib	  -­‐	  0.709uM	  
D	   Belinostat	  -­‐	  0.00325uM	   Tiva<nib	  -­‐	  0.0709uM	  
E	   En<nostat	  -­‐	  6.84uM	   Topotecan	  -­‐	  0.0138uM	  
F	   En<nostat	  -­‐	  0.684uM	   Topotecan	  -­‐	  0.00138uM	  
G	   Ima<nib	  -­‐	  20uM	   YK-­‐4-­‐279	  -­‐	  0.65uM	  
H	   Ima<nib	  -­‐	  2uM	   YK-­‐4-­‐279	  -­‐	  0.065uM	  
Figure 4.1: Plate layout for comparison to NET drug screen.
of library complexity at low cell counts and sequencing depths, we alloted five biological
replicates for each treatment. Drugs were administered at the concentrations indicated in
Fig 4.1 and incubated for 6 and 24hrs, to match the conditions of the original screen.
4.2.2 Experimental Protocol
At each time point, growth media was removed and cells were washed twice in sterile
PBS before being lysed by 15 minute room temperature incubation ( 27C) in a hypotonic
buffer containing DNase (Turbo DNase, ThermoFisher). Cells were then transferred to a
96 well mRNA capture plate, in which the walls of each well are coated with bound poly-T
sequences to capture the mRNA at its poly-A tail (TurboCapture mRNA plates, Qiagen),
following the manufacturer’s protocol. mRNA was eluted from the capture plate and trans-
ferred to a fresh 96-well plate, in which it was fragmented by heating at 95C for 6 minutes,
followed by immediate incubation on ice. Reverse transcription (RT) was carried out in this
same plate, during which well-specific bar codes were introduced, as a component of the
RT primers. The resulting single-stranded cDNA (ssDNA) was pooled and concentrated
through silica-based membrane columns (Zymo Clean and Concentrate kit, DNA protocol)
and further purified with Ampure XP beads, to remove any residual primers. Second strand
synthesis was carried out by incubation with 5U of klenow fragment (exo-), for 10 minutes
at 25C, followed by 50 minutes at 37C. The newly double-stranded cDNA (ds-cDNA) was
then purified with Ampure XP beads, as before and split into several aliquots and amplified
by PCR. Each aliquot was amplified with a different number of PCR cycles and the library
that showed the minimum amount of material necessary for sequencing was used. Using the
least amplified library helped to keep the amount of amplification closer to the linear range,
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thereby limiting the amount of PCR bias expected to be found in the resulting library.
Length-adjusted library concentrations were calculated based on measurements from an
Agilent 2100 Bioanalyzer, to establish mean library fragment length and a Qubit fluorom-
eter (Invitrogen), to measure the library concentration by mass. Libraries were submitted
to the Sulzberger Genome Center for sequencing on the HiSeq 2000 platform (Illumina).
4.2.3 Results
The sequencing data obtained after library preparation with PLATE-Seq was gener-
ally of very high quality. The low proportion of reads mapping to rRNA sequences indicated
an efficient mRNA purification (Fig 4.2A). To measure the distribution of our random primer
annealing during second strand synthesis, we mapped the distribution of reads covering each
nucleotide position of all identified genes and compared this to a previous RNA-Seq study
involving a library that was sequenced to a depth of 30M reads per sample. As shown in
Fig 4.2B, despite the greater and expected variability in the frequency of gene body coverage
in the PLATE-Seq library, full gene body coverage comparable to that of the higher-depth
sequencing run is obtained. We needed a separate study for this comparison, as this anal-
ysis was not performed in the original screen and I did not have access to that data. Gene
detection efficiency, or the rate at which genes were uniquely identified was measured both
as a function of the number of samples in the plate and of the number of mapped reads, as
shown in Fig 4.2C and D. Fig 4.2C shows the variability in identified genes between samples
on the plate, with a very similar number of genes being identified in the majority of samples
and only a very few outliers in either direction. We interpret this data to mean that the
gene detection efficiency and therefore the mRNA purification and library amplification are
fairly uniform and without obvious bias. Fig 4.2D shows that gene detection occurred very
rapidly as a function of mapped reads and saturated early, decreasing rapidly after 200,000
reads, with very few new genes being identified after 500,000 reads. This data not only
matched the gene detection rate of the same long-lost dataset that was used to compare
gene body coverage, but closely matches the theoretical threshold for effective VIPER anal-
ysis, seen in Fig 1.4. This suggests that although VIPER functions well at low read depth,
it requires a saturated gene expression library to perform optimally.
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Figure 4.2: Quality control measures of the drug screen. (A) Amount of reads mapping to
rRNA sequences. (B) The percentage of reads that covers each nucleotide position of all
detected genes scaled to 100 bins, from 5’ UTR to 3’ UTR. (C) Gene detection frequency.
(D) The number of uniquely identified genes as a function of the number of mapped reads.
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Similarity between samples was assessed using the viperSimilarity metric of the
VIPER package. The viperSimilarity compares transcription factor activity similarity be-
tween samples in the following way. For any pair of treatments A and B, it first subsets the
tails of the TF activity distribution for each treatment, selecting the 50 most differentially
active TFs in either tail. It then performeds GSEA, computing the enrichment of these
TFs in A on the full set of TFs in B. Finally, it repeats this calculation, switching B for
A. Overall, the PLATE-Seq drug treatments showed strong positive similarities to their
high-depth counterparts, as seen in Fig 4.3.
One obvious exception is entinostat, which actually shows a complete reversal of
signature between the two matched experiments. Although in any drug screen, one expects
to see some samples fail to produce consistent or even coherent results and as long as this
is not a systematic effect seen to a statistically significant degree throughout the screen,
the anomalous results can be discarded and if needed, those samples can be re-screened at
a later date. The complete reversal of the entinostat signature in this case proved more
perplexing. At first glance, one is tempted to think that a sample label was switched.
Excessive back-searching of the PLATE-Seq pipeline could not uncover any evidence of
this having happened and insufficient evidence existed concerning the original drug screen
to determine if such an event occurred then. Whatever happened appears likely to have
occurred during the original screen, based on the similarity between TF activity signatures
of PLATE-Seq-prepared entinostat and the belinostat samples. Both drugs are histone
deacetylase (HDAC) inhibitors, with very similar MoA. The two clusters that appear by
this analysis are one involving AZD8055 and MK-2206, both of which target the mTOR and
AKT pathways and the other drugs, which for this plate, consisted of a mix of inhibitors of






































































































































































































































































































































































Figure 4.3: VIPER similarities of drugs prepared in separate experiments, by either PLATE-
Seq or TruSeq
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4.3 Using PLATE-Seq to Identify Transcription Factors That
Regulate FGF-Induced Growth and Inhibition: Collab-
oration With Merrimack Pharmaceuticals
4.3.1 Motivation
The second test of PLATE-Seq, comparing it to established expression library prepa-
ration methods, consisted of using a targeted fibroblast growth factor receptor 2 (FGFR2)
antagonist to identify candidate master regulators of FGF-induced growth and growth in-
hibition for use in treating squamous cell lung cancer. There are currently only limited
treatment options available for squamous cell lung cancer [61]. Although numerous clinical
trials are investigating the FGF pathway for actionable therapeutic potential, no approved
FGF-targeted therapies currently exist. To address this, we engaged in a collaboration with
Merrimack Pharmaceuticals, who were interested in developing targeted therapies to halt
tumor-driven FGF-dependent angiogenesis for treating squamous cell lung cancer.
4.3.2 Fibroblast Growth Factor Receptor as a Therapeutic Target
FGF receptors are bound with varying affinity by a large number of ligands [69]. One
such ligand, FGF2, is upregulated in a number of cancer settings [89], [81], [66] and binds
to a subclass of FGF receptors known as the c isoforms. Cells that display FGFRc isoforms
tend to be phenotypically mesenchymal, a phenotype which carries with it a decreased
prognosis for long-term patient survival [90]. Merrimack had designed an FGFR inhibitor
that acts by competitively binding that receptor, presumably with a higher affinity than
does FGF2. They had previously tested it to show that it did, indeed, inhibit proliferation.
Because of the commercial and competitive nature of this project, I do not have access to
their data concerning binding affinity and the inhibition of proliferation. Merrimack was
interesting in characterizing the mechanism of action of their FGFR2 inhibitor. For our
part, this collaboration represented an ideal opportunity to perform technical comparisons
between PLATE-Seq and TruSeq, Illumina’s well-established expression library preparation
method. Under our agreement with Merrimack concerning publication of results, I will
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only describe the comparison of PLATE-Seq to TruSeq and the reproducibility between
biological replicates seen in the PLATE-Seq prepared samples. The following section will
describe the experiment that we performed for publication, which was based upon the results
and modifications to the protocol that we established over the course of this project.
4.3.3 Experimental Set-Up
To compare PLATE-Seq to TruSeq and also to test PLATE-Seq’s reproducibility,
I profiled two squamous cancer cell lines: colo699 and H2172. The two cell lines differ in
their response to FGF2 treatment. Colo699 expresses FGFR2c and as such, is sensitive
to treatment with either FGF2 or the inhibitor. For this reason, it is classified as the
"responder" cell line. Conversely, H2172 is a "non-responder" cell line and as such, does
not express FGFR2c and should therefore be insensitive to either treatment. Although the
greater and still ongoing collaboration involves many more responder/non-responder cell
line pairs, my contribution consisted only of developing the PLATE-Seq protocol in the
context of these two lines and performing technical comparisons to TruSeq.
The experiment consisted of treating each cell line with either FGF2 or the inhibitor
at concentrations that were empirically determined to elicit maximum responses from each
cell line by titration curve and growth assay analysis. The responder and non-responder
cell lines were each cultured in the same growth conditions. They were then treated with
their optimal concentrations of either FGF2 or the FGFR inhibitor, or as a control, with
neutral phosphate buffer (PBS), as a vehicle control. Treated cells were incubated for 6, 12
and 24 hours, after which they were lysed in buffer RLT (Qiagen), flash frozen with liquid
nitrogen and shipped to us on dry ice. The experiment was split between Merrimack’s
laboratory facilities in Massachusets and our lab here at CUMC. Cells were treated at
Merrimack’s facility, then lysed and shipped to us for RNA purification and transcriptome
library preparation.
4.3.4 Experimental Protocol
The experimental protocol for this experiment closely mirrored that used in the
comparison to the NET drug screen, detailed above, with the following alterations. In this
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formulation of the protocol, we used terminal transferase to add adenine nucleotides to the
3’ end of the ssDNA strands. These added poly-A sequences were then used as primer
annealing sites during second strand synthesis, increasing the efficiency of the reaction by
decreasing sequence complexity. This was in response to seemingly poor yields and low
complexity in previous libraries.
4.3.5 Results
The sequencing results for this experiment showed comparable gene detection effi-
ciency rates for the two methods. The deeper sequencing run (30M) detected more genes in
total than the PLATE-seq (PS) run, which was expected. Encouragingly, the difference in
detected genes between these two datasets was small. Roughly 20,000 genes were detected
across samples in the TruSeq dataset and between 14,000 and 15,000 genes were detected
across samples in the PS dataset. Unfortunately, the inhibitor treatment of the colo699 cells
in the TruSeq dataset failed to generate sufficient reads for further analysis, as shown in
Fig 4.4. As the TruSeq samples had been processed in our core facility, following standard
lab protocols, it was not possible for us to pinpoint what went wrong and we were forced




4.4 Using PLATE-Seq to Perform Drug Screening
The identification of drug treatments that are useful in diverse therapeutic settings is
a significant driving force in biomedical research [55], [68], [48]. Typical means of measuring
the efficacy of a drug for a given clinical application include protein-protein interactions,
cell death, mitochondrial respiration and cell growth as well as broader measurements of
absorption, distribution, metabolism, excretion and toxicity (ADMET), specifically related
the drug or drugs being tested [85]. A wide array of methods are routinely employed to
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Figure 4.4: Exploratory data analysis for colo699 H2172, at the 24hr time point.
Figure 4.5: Quantile normalized read distributions of PLATE-Seq and TruSeq data.
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Figure 4.6: Principle component analysis of treatment conditions between responder and
non-responder cell lines.
In the end, however, drug screening is an intensive process, essentially composed of a needle-
in-a-haystack approach, in which one must sift through thousands of candidate compounds
to find only a very few, or in many cases, one single relevant compound (Fig 4.7A). One
method that is currently underutilized in small-molecule drug screens and drug discovery is
high-throughput transcriptome sequencing (HTS), such as RNA-Seq. Although RNA-Seq
is routinely used to profile patterns of genetic changes following perturbations such as drug
treatment [99], it has not, to our knowledge, yet been used as the primary readout of a drug
screen.
RNA-seq has been used in addition to other biochemical assays as part of an in-
tegrated screening pipeline, as in [33], but not as the primary, stand-alone readout of the
screen. This is a pity, as RNA-Seq offers many practical advantages (Fig 4.7B). RNA-Seq
is a highly scalable technology. There has been considerable interest in making increasingly
multiplexed expression libraries to enable researchers to perform increasingly complex and
larger-scale sequencing experiments [37], [40], [38]. The primary impediment to making full
use of this potential scalability, however, is the price of sequencing, which, while continuing
to decline, remains prohibitively expensive for many applications. Performing large-scale
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C. Minimizing Sequencing for  
    Large-Scale Projects 
B. Advantages of RNA-Seq 
•  Many tools for analysis 
•  Stable technology 
•  Data can be reused  
•  Robust R&D in the field 
•  Ideal for network biology approaches 
Figure 4.7: A. General drug or other small molecule screening pipeline. From a pool of
thousands of candidate molecules, possibly only a single one will prove useful. B. RNA-
Seq offers a number of advantages and is the tool of choice for genomic investigations. C.
Because of the need for so many different molecules and testing conditions in a large-scale
drug screen, there is a strong need to multiplex as many experiments as possible into a
single sequencing library.
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drug screens is one highly desirable application.
Ultimately, a drug screen encompasses multiple perturbations that have genome-
wide effects on cellular networks. The lack of a genome-wide readout is, therefore, a short-
coming in that it represents a lack of potentially very valuable information. This lack is
understandable, however, as the cost of sequencing large screens, which must frequently
take into account multiple drug concentrations across several time points, is considerable.
As we progress in our ability to interrogate cellular networks at a systems level, however,
vital techniques such as large-scale drug screens stand to benefit from advances in network
biology. To do so, however, they will require genome-scale outputs.
One way to drive down the cost of multiplexing greater numbers of treatments into
a drug screen is to lower the depth at which an expression library is sequenced, thereby
allowing more samples to be sequenced in any given run (Fig 4.7C). This raises the ques-
tion of how much sequencing is sufficient for use with network techniques. Here, we show
that relatively low-depth sequencing of 500,000 to 2 million (2M) reads per sample is suf-
ficient to acquire informative treatment-specific gene expression profiles. We accomplished
this through a highly multiplexed transcriptome library preparation method. As a qual-
ity control measure, we compare our method to IlluminaâTMs TruSeq library preparation
protocol.
As a test of the PLATE-Seq method, I compared the gene expression profiles and
TF activity profiles that I obtained from treated cells with drugs, using either the PLATE-
Seq method or the well-established Illumina TruSeq protocol. The goal was to show that
expression libraries obtained via the PLATE-Seq method provided information that was at
least equivalent to those obtained by TruSeq, at the level of protein activity network analysis.
With the decreased cost of library preparation and concomitant rise in the number of
multiplexed samples per library offered by PLATE-Seq, this would demonstrate a practical
and cost-effective means for performing high throughput screening at a scale previously
unattainable for most laboratories.
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4.5 Experimental Set-Up
For this proof-of-principle screen, I selected a panel of seven drugs of known mech-
anism of action (MoA). These drugs would be administered to BT-20 cells, a basal-like
breast carcinoma cell line, at the drugs’ IC20 and libraries would be prepared from all
samples after 24 hours of exposure. Although PLATE-Seq is designed for screening sub-
stantially more treatments in a single experiment, or more conditions per treatment, such
as varying concentrations, I was constrained in the number of conditions/treatments that
I could test in this experiment by the need to make technical replicates for the TruSeq
portion of the samples. The TruSeq protocol calls for a greater per-sample RNA input than
does PLATE-Seq. The Sulzberger Genome Core Facility at Columbia University, where
the TruSeq fraction was processes, also requires a higher amount of starting material, to
hedge against any potential sample loss that may occur during the preparation process. To
accumulate the 100ng of required starting material for the TruSeq samples, half the vol-
ume of six wells per treatment had to be pooled, making for duplicate biological replicates
for each TruSeq treatment condition, versus 12 biological replicates for each condition, as
prepared by the PLATE-Seq method. Although 12 biological replicates are well more than
sufficient for PLATE-Seq, the abundance of replicates does lend strong statistical power to
the resulting analysis.
BT-20 cells were plated in a 96-well plate at an initial density of 8,000 cells per well.
They were cultured in an EMEM medium supplemented with 10% FBS and 1% pen/strep.
This density was empirically determined to be optimal, based on previous experiments
measuring the amount of purified RNA obtained after plating different quantities of cells,
as seen in Figure 4.8, grown overnight at 37C and transferred to the automation facility the
following morning, allowing for approximately 16 hours of growth to fully recover from the
effects of having been split and plated.
Once the plate was in the possession of the automation facility, all following steps
until sample pooling were performed fully robotically on the Hamilton MicroLab STAR
liquid handling robot. Each row of the plate was administered a separate drug, with final
row receiving DMSO, which is the vehicle medium for all drugs in the panel. The protocol
was then performed as described in the Methods chapter.
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Figure 4.8: RNA purified from cells cultured in 96-well plates
The drugs that were chosen for this experiment were albendazole, aprepitant, borte-
zomib, gemcitabine, crizotinib, idarubicin and mitoxantrone. Each drug except for idaru-
bicin and mitoxantrone comes from a separate class of drugs and operates in a manner
distinct from the others. Conversely, idarubicin and mitoxantrone are both antineoplastics
that work by inhibiting DNA synthesis through inhibition of topoisomerases, particularly
TOP2A. One of the desired outcomes of this experiment was to see distinct drug profiles at
both the gene expression and protein activity levels, from the libraries made using PLATE-
Seq. As a form of internal control, I felt that it was also important to see that PLATE-Seq’s
reduced depth libraries could also accurately capture the similarity that should exist be-
tween drugs with very similar MoA.
The specific drugs chosen for this experiment were drawn from a panel of drugs
that had been previously used in a much larger drug screen for a separate project taking
place in the Califano Lab, called the N-of-One project. This screen was also performed on
BT-20 cells, which gave me access to a body of data for use in planning this experiment
and will allow results obtained in this experiment to inform future aspects of the much
longer running N-of-One project. The drugs selected for this screen were based on the
following criteria: 1) they must cluster apart from each other, 2) they must have shown an
ability to reverse the gene expression and TF activity signatures, as compared to DMSO
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and untreated cells and 3) they must not be the best candidates for further screening in
the N-of-One project, so as not to scoop any of the results of that future publication. To
this end, the seven drugs selected for this experiment were done so based on a combined
method of computational direction and manual curation.
4.6 Results
4.6.1 Data Quality
Two potential sources of significant experimental noise were well-to-well variation in
RNA yield and cross talk. To quantify both of these effects, we added ERCC synthetic RNA
spike-in controls to alternating wells. This control consists of a mixture of synthetic RNA
oligonucleotides of known length, sequence and concentration. Measuring the concentration
of each mix component versus the number of recovered reads provided us with a measure
of the amount of variation across the plate. Since the spike-ins were loaded into alternating
wells, measuring the number of any reads mapping to ERCC sequences in each of the wells
provided us with a measure of the amount of cross-talk in the experiment. In the former
case, the strong linear relationship between ERCC concentration and normalized counts
shows that there was very little variation in RNA yields across the plate (Fig. 4.9). After
variance stabilization by DESeq, the fraction of potential ERCC reads mapping to wells in
which they were not loaded is negligible.
Although our PLATE-Seq run yielded approximately 2.5% of the number of reads
per sample as that of TruSeq (499,513 reads on average in PLATE-Seq vs 19,701,454 reads
on average in TruSeq), these reads captured roughly half as many genes as corresponding
TruSeq samples (9,875 genes detected, on average, for PLATE-Seq samples vs 16,913 for
TruSeq; Fig 4.9A-D), suggesting a more efficient rate of gene detection. Because PLATE-
Seq relies on fewer cycles of amplification and a smaller input than TruSeq (12 vs 16,
respectively), the number of reads per expressed gene fall closer to the linear range, re-
sulting in a faster gene detection saturation rate. To assess gene detection saturation, we
randomly sampled increasing numbers of genes from the raw data and plotted the number




































































































































































































E. Gene Detection Saturation





















Figure 4.9: ERCC Distribution and Gene Detection Rates
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principal component analysis on the GEPs of the TruSeq and PLATE-Seq datasets. In this
analysis, a single DMSO sample, shown in Fig 4.10, was seen to be a strong outlier and was
therefore removed from the analysis. Following outlier removal, biological replicates of mi-
toxantrone, bortezomib, crizotinib and idarubicin were seen to cluster together in very tight
shot groupings, while albendazole, aprepitant and gemcitabine replicates clustered together
with DMSO. Although I had expected albendazole and aprepitant to cluster close to DMSO,
as neither of these drugs is known to have profound effects on gene expression networks, I
was surprised and mildly disappointed to see the gemcitabine join them, as gemcitabine has
a similar MoA to mitoxantrone and idarubicin and is expected to have a correspondingly
strong effect on gene expression in treated cells. Nonetheless, a negative result like this
one is to be expected from any drug screen of sufficient size. This result merely highlights
the natural variability inherent in large molecular screens. Discrepancies between biological
replicates in RNA-Seq experiments are not unexpected, owing to a diverse set of factors,
ranging from simple pipetting error [60] to naturally occurring stochastic gene expression
variation. [64].
Despite such potential for unpredictability, PLATE-Seq compared remarkably well
to TruSeq on a number of other QC measures. Differential gene expression was evaluated
using DESeq2 [54]. Both datasets displayed a linear decrease in dispersion, or variability
in gene expression values, with increased mean normalized counts. Only in the case of the
TruSeq library, did the dispersion appear to reach saturation, as seen by the flattening of
the curve at the highest range of the mean normalized counts, Fig 4.11. This is expected,
given the higher depth of sequencing in that library. Measurements of expression vs fold
change and of fold change vs significance, as measured by -log10(p-value), also showed
highly compatible results. In both cases, the same genes showed up as being the most
significant in both datasets. As a final measure of PLATE-Seq’s reproducibility, we noted
that gene expression profiles overall compared very positively between the majority of both
biological and technical replicates, as seen in Fig 4.12. Taken together, these results gave








































































































































































































Figure 4.10: Principal component analysis for PLATE-Seq samples, with DMSO replicate
outlier
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PLATE_Seq Dispersions, Undetected Genes Removed




























TruSeq Dispersions, Undetected Genes Removed
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D. VIPER Similarity Between Library Preparation MethodsFigure 4.12: Comparison of gene expression signatures across all samples and both plat-
forms.
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4.6.2 Large-Scale Drug Screen
Because PLATE-Seq was designed primarily as a tool for large scale screens, its
main advantage, that of increasing multiplexing while reducing cost, lies in such a large-
scale setting. Our final experiment was therefore to test PLATE-Seq’s performance in
such a setting and to apply our sequencing results to network biology methods capable
of utilizing PLATE-Seq’s low read depths. For this, we conducted a larger drug screen
and analyzed the results using the VIPER algorithm. Our screen consisted of 69 drug
treatments, administered at two concentrations and assayed at two time points. The chosen
concentrations were the IC20 for each drug and 1/10 of the IC20. The drugs used in this
screen consisted of a broad selection of drug classes, ranging from targeted antibodies, to
antivirals to anthelmintic medications directed against eukaryotic parasites (see Table 1
in the appendix). The screen was performed in the same BT-20 cell line as before. The
drugs were selected based on cell survival data that had previously been acquired by the
Automation Core Facility at CUMC. The procedure for manipulating these plates and
constructing libraries from them was the same as that used in the single plate setting.
The procedure used to build this library was identical to that of the smaller-scale
library in the previous section. Mapped reads and gene detection rates were also compa-
rable (Fig 4.13). As a further measurement of data quality, we calculated the correlation
distributions between all samples and between biological replicates across all plates and
plotted them as densities, as seen in Fig 4.14. This shows that wells that were treated with
the same drug are more similar to each other than to wells treated with different drugs. We
further compared replicate-vs-non-replicate correlations in our PLATE-Seq data to those
in other publicly available datasets. For this comparison, we chose drug perturbation ex-
pression data from the CMAP and LINCS databases. Although these expression sets were
built using different technologies; Affymetrix in the case of CMAP and Nanostring in that
of LINCS, all datasets consist of drug perturbation experiments highly similar to our own
and contain biological treatment replicates. In theory, any cells that were treated in the
same way, with the same perturbagens and under the same conditions, should correlate
well to each other. What Fig 4.14 shows it that, compared to the other datasets, replicates
assayed using PLATE-Seq are considerably better correlated. This suggests that the data
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Figure 4.13: Detected genes vs mapped reads for each plate in the large-scale drug screen.
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Figure 4.14: Correlation densities between all samples vs between biological replicates.
obtained using PLATE-Seq is both of high quality and is less noisy than other widely-used
datasets obtained through prior technologies.
We evaluated sample clustering using the t-Distributed Stochastic Neighbor Em-
bedding (t-SNE) technique. Similar to techniques such as principal component analysis
(PCA) or multi-dimensional scaling (MDS), t-SNE is a method for reducing dimensionality.
It is particularly well-suited to visualizing scenarios involving high-dimension datasets, such
as ours. Analysis by t-SNE showed that samples from the same plate were clearly separate
from samples from diverse plates at the level of gene expression, as seen in Fig 4.15. Within
each plate-specific grouping, biological replicates of the same concentration tended to clus-
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ter together. Less frequently, replicates of different concentrations also clustered together,
indicating the effects of each treatment could vary strongly by concentration, in keeping
with our current understanding of drug dosing.
To examine the efficacy of VIPER, we selected two drug treatments for closer inves-
tigation. For this analysis, we selected vorinostat and temsirolimus, based on their clustering
by t-SNE. In the case of both drugs, each pair of replicates of the same concentration clus-
tered tightly together at 24 hours and each treatment was sufficiently far from the other,
that we reasoned that we would obtain clearly differentiable results between the two.
4.6.3 Challenges in Applying Virtual Proteomics
The motivation driving the development of PLATE-Seq was to achieve greater ex-
perimental throughput using a combination of biochemical and computational methods.
Specifically, we believed that lower-depth sequencing could increase the number of experi-
ments sequenced in a single run and that this data would be useful to network techniques
such as the virtual proteomics offered by the VIPER algorithm. To this end, I spent a con-
siderable amount of time analyzing our sequencing data with the hope of acquiring verifiable
and biologically meaningful results. Doing so proved to be a major challenge and highlights
at least one significant obstacle to leveraging the full power of the VIPER algorithm in an
investigational setting.
The VIPER algorithm itself consists of a relatively simple and uncontroversial the-
ory: that the differential activity of a TF can be inferred from the differential expression of
its transcriptional targets. To put this theory into practice, a sufficiently accurate network
of genetic interactions, or interactome, is needed. This is where the problems begin. The
accurate identification of TFs and their transcriptional targets constitutes a massive and
ongoing undertaking [14]. Different TFs are active under different and specific conditions
and identifying these patterns of activity is not a trivial task. Although several techniques
have been pioneered to accomplish this task, none comes without significant caveats. These
techniques can be split broadly into two classes: biochemical methods and bioinformatic
methods.
Despite the sophistication of the methods that have been developed to infer gene
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Figure 4.15: Sample grouping based on t-SNE.
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regulatory networks, all of those algorithms rely first on the prior identification of which
genes constitute putative TFs and which constitute putative targets. The first transcription
factors were discovered in focused, single-gene studies [49]. Naturally, we have sought ways
to increase the throughput of those experiments in order to build whole gene regulatory
networks. Among the biochemical methods, chromatin immunoprecipitation followed by
sequencing (ChIP-seq) and ChIP followed by microarray hybridization (ChIP-chip) studies
both seek to identify TFs in a high-throughput manner. Positive results in either setting,
however, frequently depend on being able to identify other underlying conditions that may
lead to DNA binding by the putative TFs [29].
Given the amount of sequence data available and the relatively low overhead costs
involved in conducting bioinformatic research, as compared to bench-top biochemistry, a
number of bioinformatic methods have been applied to the identification of TF-target in-
teractions. As before, none of these come without caveats. For instance, many algorithms
exist to identify and map conserved transcription factor binding sites (TFBS), but sequence
conservation is not enough to precisely identify the binding TF ([44], [16], [73]).
My own lab’s foundational method, ARACNe, was an attempt to streamline the
process of TF-target interaction identification through one of the earliest applications of
mutual information theory to the biological sciences. As stated earlier, ARACNe makes
the assumption that while not linear, some relationship should exist between the expression
of a TF and that of its targets. While this is unlikely to be true on any but the broadest
scale, it did enable the most rapid and high-throughput analyses of these relationships
to be made at the time. Furthermore, through careful curation of the lists of identified
TFs and non-TFs that were used as input and clever experiments, it did serve as a useful
method in ibvestigations into the GRNs underpinning some cancer contexts, most notably
glioblastoma [10] and in B cells [51]. An unfortunate, but critical negative result of my
own studies, which highlights the limits of network inference algorithms, is that our current
breast carcinoma networks may not be as reliable we need them to be.
A considerable amount of time was spent analyzing VIPER results that I obtained
using a breast carcinoma interactome that was composed of three classes of regulators:
TFs, co-TFs and signaling molecules. The TF component was obtained as described pre-
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viously. What I only discovered later, was that the co-TF network was inferred not from
direct experimental data, but by GO terms [2] that were deemed likely to be associated
with transcription factors. The specific GO terms used to generate the co-TF list were
GO:0003712 (transcriptional coregulation) and GO:0005634 (nuclear localization). While
these terms may represent many co-transcription factors, it is unlikely that all genes repre-
sented by those terms will actually be co-TFs, thus adding noise to an already noisy system.
The signaling proteins and their targets composed an even more abstracted set of poten-
tial regulatory interactions than that of the co-TFs. This network was inferred by running
ARACNe on RNA-Seq data and using a list of known signaling molecules rather than one
composed of transcription factors. Although the ARACNe algorithm will treat these inputs
the same and look for statistically significant relationships between the list of regulators
and the other genes in the RNA-Seq raw counts data, this resulting statistical relationships
are unlikely to have any biological relevance, since the methods itself rests on an untrue
assumption; that the expression of signaling molecules (predominantly phosphatases and
kinases) in any way tracks that of differential gene expression. Signaling molecules operate
on much smaller timescales than those relevant for gene expression. Because phosphoryla-
tion reactions are measured on the order of milliseconds to seconds [86], while transcription
takes minutes to occur [58], RNA-Seq data that is not part of a time course trial stands
little to no chance of catching measurements on the relevant timescales.
As an example of the perils of building a network in this way, we found that
VIPER failed to detect any differential activity whatsoever of mTOR, the extremely well-
characterized target of the rapamycin analogue temsirolimus [12], [41], [76], [95], as seen in
the bottom of Fig 4.16. A further challenge came in trying to reconcile the other regulators
inferred as most differentially active with the gene products known to interact with that
drug or its targets. At best, we could only note that some of the inferred regulators operated
within the same pathways known to be perturbed by the treatments. Even in this case,
however, most of these pathways were related to cell division and cell death, both of which
are known to be perturbed in all cases where a drug treatment stresses cells. Because of
this, we were unable to unambiguously separate the action of any specific drug from that




































































































































Figure 4.16: The results of master regulator analysis for BT-20 cells treated with tem-











































































































































































































































































































Temsirolimus MARINA Results 
Figure 4.17: The results of master regulator analysis for BT-20 cells treated with tem-
sirolimus, using an interactome built using only TFs and co-TFs.
To improve the results of VIPER analysis, I first removed the signaling genes from
the breast carcinoma interactome. For this analysis, I chose to focus on two treatments,
temsirolimus and vorinostat, as replicates from these two appeared to cluster tightly to-
gether, while the two treatments separated well from each other, as seen in Fig 4.15. The
results from this analysis were not significantly easier to explain. In the case of temsirolimus,
the only potentially useful finding was that a slight increase in activity was measured for
the gene p27, which would be expected from mTOR inhibition (Fig 4.17). Even so, the
inferred activity for p27 was not strong and worse, no other differential activity was found
in other known targets of the mTOR pathway.








































































































































































































































































































Vorinostat, MARINA Results 
Figure 4.18: The results of master regulator analysis for BT-20 cells treated with vorinostat,
using an interactome built using only TFs and co-TFs.
though in the analysis of this treatment, using the TF and co-TF combined interactome, we
inferred the differential down-regulation of two HDACs, HDAC7 and HDAC 10 (Fig 4.18),
we could find no evidence that these were known targets of vorinostat. Known HDAC
targets were not found to be differentially regulated in this dataset. Perhaps interestingly,
we noticed that the down-regulation of HDAC7 and HDAC10 peakeded 6 hours, which is
in keeping with the pharmacokinetics of vorinostat, in which the mean serum concentra-
tion has been observed to peak at roughly 6 hours [39]. In the absence of more evidence,
however, we felt that these data made a very unconvincing argument for the efficacy of this
analysis as a screen for drug effect.
Finally, I trimmed the interactome to only TFs, as the ARACNe-inferred TF-target
interactions are arguably the most likely of the categories to be biologically true and rele-
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vant. Although TF expression does not linearly correlate with target expression, if they are
related at all, this network presents the least abstracted set of possible regulatory interac-
tions of the overall breast carcinoma interactome. The results of this analysis were slightly
more encouraging than those of the last two, although were still somewhat shy of being
truly convincing. Figure 4.19 shows that we inferred the differential activity of one known,
one suspected and one possible regulatory targets of mTOR inhibition. The known target
of mTOR inhibition is HMGA1, which we found to be differentially down-regulated at 24
hours post-treatment. mTOR is known to upregulate the expression of HMGA1 [6]. It re-
mains unclear whether we should actually expect to infer a reduction in the transcriptional
activity of HMGA1 24 hours after mTOR inhibition, although this seems like a reasonable
hypothesis. FOXM1 and STAT6 were found to be down- and up-regulated, respectively.
Increased transcriptional activity of FOXM1 is a known downstream effect of mTOR phos-
phorylation by AKT [52], [70], although to our knowledge, the effect of mTOR inhibition on
FOXM1 has not been directly investigated, relegating this result to being logically plausible,
but unconfirmed. A possible regulatory interaction between mTOR and STAT6 has been
suggested in the past [75], but to our knowledge, never confirmed. Finally, PA2G4/EBP1
was inferred to be strongly down-regulated by 24 hours. The ambiguity of these master
regulator analysis results, coupled to the clear clustering pattern observed in the t-SNE
plot, suggest that the quality of our available network represents a significant impediment
to the application of network methods such as VIPER.
Despite these obstacles, we have successfully developed an efficient and scalable
protocol that is cheap enough to allow RNA-Seq to be used as a readout for HTS screens,










































































































































































































































































































Temsirolimus MARINA Results 
Figure 4.19: The results of master regulator analysis for BT-20 cells treated with tem-




PLATE-Seq is a highly efficient expression library preparation method that can be
readily adapted to a number of experimental pipelines.
5.1 Clinical Applications
As method for performing drug screening in an expedient and low-cost manner,
PLATE-Seq is an obvious target for clinical applications. In particular, PLATE-Seq and its
related suite of analytic tools are well-suited to assisting in the investigation of two clinical
objectives:drug repositioning and the search for personalized drug therapy regimens.
5.1.1 Drug Repositioning
The past decades have seen a significant decline in the rate of new drug discovery
[62]. Discovering a novel therapeutic compound and successfully shepherding it through the
trial and approval process requires significant investments of time and money and suffers
from a very low rate of success [22]. One strategy that has been gaining traction in recent
years consists of finding novel uses for drugs that are already on the market, a process
variably known as drug repurposing or drug repositioning [13] (Fig 5.2).
The primary advantages to drug repositioning are reduced costs and development
times. It is estimated to take roughly 17 years and $2.6 billion dollars to bring a new drug
to market in the United States [59]. With the advent of drug repositioning, the discovery
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Figure 5.1: Timescales involved in drug discovery vs repositioning, McCabe, et al., 2015
of novel applications for combinations of drugs takes on average only 3 - 12 years (Fig 5.1).
Repositioning also offers the distinct advantage of beginning a study with compounds that
are already proven to be safe and for which a wealth of information concerning pharmacoki-
netics, toxicities, bioavailability and dosing is already available, essentially bypassing Phase
I of the clinical testing process.
Despite the cost savings involved in beginning a drug trial with drugs that are
already proven safe, testing all possible combinations of a sufficiently large set of drugs
remains a significant financial consideration. Testing pair-wise combinations of the roughly
2,000 FDA-approved drugs [46] in one cell line and at a single concentration and time point
would result in nearly 2 million combinations. Realistically, each drug pair would have to
be tested in multiple conditions, vastly increasing the cost of the investigation. Although
not all drugs might need to to tested in combination in a given investigation, even a more
reasonable number, such as 100 drugs represents a large endeavor. This is the ideal setting
for a technology such as PLATE-Seq, which offers a high-throughput genome-based means
for interrogating drug effects at reduced cost and increased multiplicity. No single drug
67
Figure 5.2: Drugs that have been repositioned for use beyond their original specifications.
repositioning investigation need be comprehensively large on its own as long as more labs
have the means to pursue these investigations. Another benefit of RNA-Seq data is that
it exists in an easily shared digital form. The more that labs are able to pursue drug
repositioning studies, the more information will be available to all, allowing a robust use of
what promises to be a rapidly expanding knowledge base. PLATE-Seq promises to serve
as a key component of the already growing drug repositioning effort, as well as that of the
related topic of drug synergy.
5.1.2 Drug Synergy
One of the most desired outcomes of testing combinations of drugs is the identifica-
tion of those combinations, in which the joint action of the combined drugs is greater than
the sum of their constituent parts. Broadly, there are three outcomes to any drug com-
bination. First, the drugs in question may perform in an additive manner, wherein their
combined effects amount to the sum of their individual effects. Second, they may interact
antagonistically, reducing the effects of each drug. Finally, they may act superadditively. It
is this last effect that is considered most desirable in any drug combination. Combination
drug therapy has long been used to treat a number of ailments, most notably cancer, where
single-drug chemotherapy regimens have, in fact, become quite rare.




Figure 5.3: Drug synergy occurs when drugs affect different pathways that lead to the same
cellular outcome.
agents. A significant reason that synergy is a desirable effect is because a synergistic effect
is one in which drugs act on different targets that lead to the same end result, thereby
overcoming a cellular network’s natural robustness to perturbation (Fig 5.3). Regulating
another compound’s absorption and distribution, modulating the cell’s growth properties,
inhibiting compound degradation and inhibiting pathways that induce resistance or reducing
the other compound’s toxicity are some of the ways, in which one compound might sensitize
a cell to another compound, leading to synergistic effects. [5]
Establishing synergistic effects is not a trivial task. Not only are there millions of
potential drug combinations [53], but the dose at which a given drug proves both safe and
effective in a single-drug setting may differ from its most effective dose in combination with
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another drug [84], adding a considerable layer of complexity to the matter. This requires
testing each drug in a candidate synergy pair at multiple concentrations, after having first
tested numerous combinations to identify this candidate pair. Combinatorial drug testing
on this scale remains financially and logistically prohibitive.
The integration of genomic and proteomic information can greatly facilitate the
search for synergistic drug combinations. Every drug will have defined effects on cellular
networks, both at the level of gene expression and of protein activity. Given sufficiently
accurate networks, describing the characteristic alterations that are specific to each drug at
each dose will allow predictions to be made, concerning which drugs to test in combination,
leading to a more targeted approach. Nonetheless, using commercial transcriptome library
preparation kits and sequencing to high depth still represents a cost that most labs simply
cannot afford. The PLATE-Seq + VIPER pipeline of transcriptome library prep and virtual
proteomics can significantly streamline this process. Using TF activity, rather than full gene
expression profiles to characterize drugs’ effects first allows for many more drug effect profiles
to be acquired through expression library sequencing. Predictions of potential synergistic
pairs can be based on these profiles and each pair tested across a range of concentrations
and time points.
5.1.3 Personalized Medicine
One of the strongest ideas to pass through the field of biomedical research is the
concept of personalized medicine, wherein therapies are tailored to an individual based on
their unique genetic profile [31]. The idea of personalized treatments has taken particular
hold in the field of cancer research, where the current understanding of cancer is that each
cancer is specific to the afflicted individual. To date, genomic information only constitutes
one part of a highly integrated set of data used to compile a profile of a person’s health.
These data include health risk assessment, family health history, and clinical decision sup-
port for complex risk and predictive information. Personal genomic data remains a small
part of a patient’s complete medical profile for two reasons. The first is that it is easily the
hardest information to collect and the second is that we are still learning how to interpret
personal genomic data in actionable ways [72], [3].
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A significant challenge in interpreting personal genomic results stems from small
sample sizes. This could be improved with access to cheaper, faster genomic diagnostic
tools, of which PLATE-Seq promises to be a part. Although PLATE-Seq can certainly be
adapted to a clinical setting, it is important to take stock of its limits in this regard. First,
because the economical gains of this technique stem from sequencing at a very low depth,
it cannot be used to look for mutations or SNPs. However, preliminary data suggest that
little sequencing depth is needed to classify patients into different disease subtypes, such as
in the case of breast cancer [74], [97]. Because disease subtypes bear diagnostic value [83],
[36], as those subtypes become more complete and as our understanding of the molecular
profiles of disease subtypes grow, techniques such as PLATE-Seq are well-positioned for
vital future clinical uses.
One obstacle to overcome in developing the PLATE-Seq method into a clinical
tool consists of adapting the tissue culture methods involved in library preparation for use
with fresh patient-derived tumor biopsies. It is well-known that cell lines are imperfect
models of the conditions that regularly afflict patients. It would be considerably better
to be able to test biological responses to treatment regimens directly on excised patient
tissue. Although this would not address all questions of drug delivery and penetrance, it is
difficult to imagine anything that could serve as a better model for patient cell response.
Several technical challenges would have to be overcome to achieve this goal. A protocol to
extract and transfer the tissue would need to be established, followed by one to administer
treatments and disrupt the tissue to extract high-quality mRNA from it, which is not always
a trivial task in the context of primary tissue samples.
5.2 Dissecting the Physiographical Landscape of Gene Reg-
ulatory Interactions
With effective mRNA extraction procedures, another interesting application of
PLATE-Seq would be the three dimensional mapping gene regulatory landscapes of com-
plex tissues, from solid tumors to healthy but heterogeneous tissues such as brain slices.
Intratumor heterogeneity is a well-known phenomenon [101], thought to occur predomi-
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nantly through the expansion of different clonal populations. Another driver of intratumor
heterogeneity is the tumor environment itself [65]. The interior of a tumor is a highly anoxic
place compared to its edges and the diverse challenges presented to the cells in either en-
vironment will elicit diverse network effects, likely resulting in distinct drug responses. It
would be highly informative to be able to map the changing genetic regulatory landscape
of these tumors as a function of physiographic location. Such an approach could be ex-
tended to complex tissues other than tumors, such as liver and brain tissue. Besides the
practical knowledge that this would bring concerning drug sensitivity and response, this
would also shed light on fundamental questions surrounding the complex interplay between
environmental conditions and cellular development.
5.3 Pooled Expression Libraries of Pooled shRNA Libraries
Similar to chemical perturbations, RNA interference, or RNAi, is a powerful and
well-established way of interrogating gene function [80]. One advantage that RNAi has
over small molecule chemicals is that RNAi perturbations are highly targeted to specific
nucleotide sequences, whereas this is not the norm with small synthetic chemicals. Recent
advances in the development of pooled shRNA libraries have enabled the parallel analysis
of populations of cells, wherein different genes are suppressed in different cells [79], allowing
for a much more fine-grained analysis of gene function than has previously been possible.
In the da Silva study, the authors sought to identify genes essential for synthetically lethal
genetic interactions through shRNAs that were selectively depleted from populations. To
this end, they tested pools containing 6,000, 10,000 and 20,000 shRNA constructs at
different scales and at varying levels of population complexity. They infected cells with
their pooled libraries at sufficiently low multiplicities of infection (MoI), with the goal of
infecting each cell with, on average, a single shRNA-bearing virus. With each shRNA bar-
coded for deconvolution later in the process, gene expression profiling was performed using
microarrays and the data was analyzed using the EDGE package of microarray analysis
tools [50]. Genes identified as candidates from this analysis were further investigated by a
second screen, in which candidate gene-specific shRNA sequences were coupled to a GFP
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Figure 5.4: Pooled shRNA screening process. Da Silva, et al., 2008
reporter, to link shRNA expression with target gene knockdown efficiency (Figure 5.4).
A key strength of this study lay in demonstrating an actionable method for perform-
ing simultaneous genome-wide knockdown studies. Despite the high degree of multiplexing
in library preparation, however, the cost and labor of this study were increased by the au-
thors’ reliance on microarrays for differential gene expression analysis and on GFP-coupled
reporter vectors. A number of advantages would be gained by coupling this shRNA pooling
scheme to the PLATE-Seq pooled expression library method.
The chief advantage of the pooling of these pooled library strategies lies in multiplic-
ity. Twenty thousand bar-coded shRNAs distributed among 4,000 to 8,000 cells per well in a
96-well plate could easily translate into between 384,000 and 768,000 single-gene knockdown
expression profiles. This scale of gene silencing offers a means to rapidly generate the most
fine-grained GRNs to date. To paraphrase Tom hanks in A League of Their Own, if it was
easy, everyone would already be doing it. The greatest challenge in pursuing this ’pool of
pools’ expression profiling strategy lies in deconvoluting not only which bar-coded shRNA
comes from which well, but from which individual cell, as their would be a heterogeneous
mix of cells in any population, each infected with a distinct shRNA construct.
Although the challenges of properly constructing and deconvoluting such a library
are not trivial, the technology exists to act upon them. History has shown repeatedly that
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where desire is matched by means, ingenuity does not lag far behind. Arguably the greatest
challenge in systems biology is that of constructing networks that accurately represent the
biological systems that they were designed to model. Genome-wide combinatorial gene
silencing would be a significant step forward in constructing such networks.
One disadvantage of using RNAi concerns the occurrence of off-target effects. The
efficiency for any given siRNA construct is somewhat unpredictable and therefore construct
testing is usually required to accurately interpret results. In a pooled setting, some am-
biguity in target specificity is inevitable, as no reasonable method exists to test siRNA
constructs at the magnitude required for high-throughput screening. Pooled CRISPR [78],
[17] libraries, while being confronted with the same design challenges as in the case of
shRNA libraries, would at least prove to be an improvement over RNAi in terms of target
specificity .
Systems biology is poised to enter the realm of truly big data, promising to make
powerful use of greater and greater amounts of data, while simultaneously making the results
ever more relevant on a very personal level. PLATE-Seq and related technologies are going
to play an important role in the development of this field, which is still very much in its
infancy. We are, in essence, still learning to speak the language of the cell as a complete
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Appendix A Abbreviations Used Throught the Text
ADMET ... Absorption, distribution, metabolism, excretion and toxicity
BN ... Bayesian network
cDNA ... Complementary DNA
DGE ... Differential gene expression
dsDNA ... Double-stranded DNA
GBM ... Glioblastoma
GEP ... Gene expression profile
GRN ... Gene regulatory network
HDAC ... Histone deacetylase
HTS ... High-throughput screening
MoA ... Mechanism of action
MoI ... Multiplicity of infection
mRNA ... messenger RNA
rRNA ... ribosomal RNA
ssDNA ... Single-stranded DNA
85






























Simvastatin HMG-CoA reductase inhibitor
Gemcitabine Antineoplastic
Candesartan cilexetil Angiotensin II receptor antagonist




Adefovir Reverse transcriptase inhibitor






Nilvadipine Ca2+ channel blocker
Temsirolimus mTOR inhibitor
Triflupromazine Antipsychotic

























Appendix C Examples of Code Used in Analyses
C.1 Differential Gene Expression Analysis
1
2 l i b r a r y (DESeq2)
3
4 load ( " smal lScreen_truseq_deseqObj . rda " )
5 load ( " smal lScreen_p l a t e s e q_deseqObj . rda " )
6
7 # Get DGE r e s u l t s & p lace in to an o b j e c t
8 # PLATE−Seq
9 r e s <− r e s u l t s ( dds )
10 t a b l e ( r e s $padj <0.05)
11 ## Order by adjusted p−value
12 r e s <− r e s [ order ( r e s $ padj ) , ]
13 ## Merge with normal ized count data
14 r e sdata <− merge ( as . data . frame ( r e s ) , as . data . frame ( counts ( dds , normal ized=TRUE
) ) , by=" row . names " , s o r t=FALSE)
15 names ( re sdata ) [ 1 ] <− " Gene "
16
17 # TruSeq
18 r e s2 <− r e s u l t s ( dds2 )
19 t a b l e ( r e s2 $padj <0.05)
88
20 ## Order by adjusted p−value
21 r e s2 <− r e s2 [ order ( r e s2 $ padj ) , ]
22 ## Merge with normal ized count data
23 re sdata2 <− merge ( as . data . frame ( r e s2 ) , as . data . frame ( counts ( dds2 , normal ized=
TRUE) ) , by=" row . names " , s o r t=FALSE)
24 names ( re sdata2 ) [ 1 ] <− " Gene "
25
26 # MA plot , PLATE−Seq
27 maplot <− f unc t i on ( res , thre sh =0.05 , l a b e l s i g=TRUE, textcx =1, . . . ) {
28 with ( res , p l o t ( baseMean , log2FoldChange , pch=20, cex =.5 , l og=" x " ) , . . . )
29 with ( subset ( res , padj<thresh ) , po in t s ( baseMean , log2FoldChange , c o l=" red " ,
pch=20, cex =1.5) )
30 i f ( l a b e l s i g ) {
31 r e q u i r e ( c a l i b r a t e )
32 with ( subset ( res , padj<thresh ) , textxy ( baseMean , log2FoldChange , l ab s=Gene ,




36 # MA plot , TruSeq
37 maplot2 <− f unc t i on ( res2 , thresh =0.05 , l a b e l s i g=TRUE, textcx =1, . . . ) {
38 with ( res2 , p l o t ( baseMean , log2FoldChange , pch=20, cex =.5 , l og=" x " , . . . ) )
39 with ( subset ( res2 , padj<thresh ) , po in t s ( baseMean , log2FoldChange , c o l=" red " ,
pch=20, cex =1.5) )
40 i f ( l a b e l s i g ) {
41 r e q u i r e ( c a l i b r a t e )
42 with ( subset ( res2 , padj<thresh ) , textxy ( baseMean , log2FoldChange , l ab s=Gene




46 # Volcano plot , PLATE−Seq
47 vo l canop lo t <− f unc t i on ( res , l f c t h r e s h =2, s i g t h r e s h =0.05 , main=" Volcano Plot "
, l egendpos=" bottomright " , l a b e l s i g=TRUE, textcx =1, . . . ) {
48 with ( res , p l o t ( log2FoldChange , −l og10 ( pvalue ) , pch=20, main=main , . . . ) )
49 with ( subset ( res , padj<s i g t h r e s h ) , po in t s ( log2FoldChange , −l og10 ( pvalue ) ,
pch=20, c o l=" red " , . . . ) )
50 with ( subset ( res , abs ( log2FoldChange )>l f c t h r e s h ) , po in t s ( log2FoldChange , −
l og10 ( pvalue ) , pch=20, c o l=" orange " , . . . ) )
51 with ( subset ( res , padj<s i g t h r e s h & abs ( log2FoldChange )>l f c t h r e s h ) , po in t s (
log2FoldChange , −l og10 ( pvalue ) , pch=20, c o l=" green " , . . . ) )
52 i f ( l a b e l s i g ) {
53 r e q u i r e ( c a l i b r a t e )
54 with ( subset ( res , padj<s i g t h r e s h & abs ( log2FoldChange )>l f c t h r e s h ) , textxy (
log2FoldChange , −l og10 ( pvalue ) , l ab s=Gene , cex=textcx , . . . ) )
55 }
56 l egend ( legendpos , x j u s t =1, y j u s t =1, legend=c ( paste ( "FDR<" , s i g th r e sh , sep=" " ) ,
paste ( " | LogFC|> " , l f c t h r e s h , sep=" " ) , " both " ) , pch=20, c o l=c ( " red " , " orange "
89
, " green " ) )
57 }
58
59 # Volcano plot , TruSeq
60 vo l canop lo t2 <− f unc t i on ( res2 , l f c t h r e s h =2, s i g t h r e s h =0.05 , main=" Volcano
Plot " , l egendpos=" bottomright " , l a b e l s i g=TRUE, textcx =1, . . . ) {
61 with ( res2 , p l o t ( log2FoldChange , −l og10 ( pvalue ) , pch=20, main=main , . . . ) )
62 with ( subset ( res2 , padj<s i g t h r e s h ) , po in t s ( log2FoldChange , −l og10 ( pvalue ) ,
pch=20, c o l=" red " , . . . ) )
63 with ( subset ( res2 , abs ( log2FoldChange )>l f c t h r e s h ) , po in t s ( log2FoldChange , −
l og10 ( pvalue ) , pch=20, c o l=" orange " , . . . ) )
64 with ( subset ( res2 , padj<s i g t h r e s h & abs ( log2FoldChange )>l f c t h r e s h ) , po in t s (
log2FoldChange , −l og10 ( pvalue ) , pch=20, c o l=" green " , . . . ) )
65 i f ( l a b e l s i g ) {
66 r e q u i r e ( c a l i b r a t e )
67 with ( subset ( res2 , padj<s i g t h r e s h & abs ( log2FoldChange )>l f c t h r e s h ) , textxy (
log2FoldChange , −l og10 ( pvalue ) , l ab s=Gene , cex=textcx , . . . ) )
68 }
69 l egend ( legendpos , x j u s t =1, y j u s t =1, legend=c ( paste ( "FDR<" , s i g th r e sh , sep=" " ) ,
paste ( " | LogFC|> " , l f c t h r e s h , sep=" " ) , " both " ) , pch=20, c o l=c ( " red " , " orange "
, " green " ) )
70 }
71
72 # Plot QC measures
73 pdf ( "DESeq2_QC_Plot s . pdf " , w=12, h=18, p o i n t s i z e = 18)
74 par ( mfrow=c (3 , 2 ) )
75 p lotDi spEst s ( dds , main="PLATE_Seq Disper s ions , Undetected Genes Removed" )
76 p lotDi spEst s ( dds2 , main=" TruSeq Disper s i ons , Undetected Genes Removed" )
77
78 maplot ( resdata , main="PLATE−Seq MA" )
79 maplot ( resdata2 , main=" TruSeq MA" )
80
81 vo l canop lo t ( resdata , l f c t h r e s h =1, s i g t h r e s h =0.05 , t extcx =.8 , xlim=c ( −2.3 , 2) ,
main="DGE, PLATE−Seq " )
82 vo l canop lo t ( resdata2 , l f c t h r e s h =1, s i g t h r e s h =0.05 , t extcx =.8 , xlim=c ( −2.3 , 2) ,
main="DGE, TruSeq " )
83 dev . o f f ( )
Algorithm 6.1: Estimate differential gene expression using DESeq2
C.2 Computing and Plotting t-SNE
1
2 # Mult id imens iona l s c a l i n g o f the N−of −1 data
3
90
4 # load gene e x p r e s s i o n s i g n a t u r e s
5 load ( " ~/ P r o j e c t s /PLATE−Seq/N1/ BreastCancerScreen / nof1_bctx_normal izedCts . rda " )
6 # load v ipe r o b j e c t
7 load ( " ~/ P r o j e c t s /PLATE−Seq/N1/ BreastCancerScreen / nof1_vipermat . rda " )
8
9 # TSNE
10 l i b r a r y ( t sne )
11 # separa te s i g n a t u r e o b j e c t s by time po int
12 gep6 <− s1 [ , c ( 1 : 9 2 , 1 8 5 : 2 7 6 , 3 6 9 : 4 6 0 ) ]
13 gep24 <− s1 [ , c ( 9 3 : 1 8 4 , 2 7 7 : 3 6 8 , 4 6 1 : 5 5 2 ) ]
14
15 vp6 <− vp1 [ , c ( 1 : 9 2 , 1 8 5 : 2 7 6 , 3 6 9 : 4 6 0 ) ]
16 vp24 <− vp1 [ , c ( 9 3 : 1 8 4 , 2 7 7 : 3 6 8 , 4 6 1 : 5 5 2 ) ]
17
18 tgep6 <− t sne ( t ( gep6 ) )
19 tgep24 <− t sne ( t ( gep24 ) )
20 tvp6 <− t sne ( t ( vp6 ) )
21 tvp24 <− t sne ( t ( vp24 ) )
22
23 pdf ( " bt20_tsne_a l lSamples_withLabels . pdf " , h=20, w=20, p o i n t s i z e =18)
24 par ( mfrow=c (2 , 2 ) )
25 p lo t ( tgep6 , pch=20, c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1 " , ylab=" P r o j e c t i o n
2 " , main="TSNE of Gene Express ion P r o f i l e s , 6hr " )
26 t ex t ( tgep6 [ , 1 ] , tgep6 [ , 2 ] , l a b e l s=colnames ( gep6 ) , cex =0.4)
27
28 p lo t ( tgep24 , pch=20, c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1 " , ylab=" P r o j e c t i o n
2 " , main="TSNE of Gene Express ion P r o f i l e s , 24 hr " )
29 t ex t ( th i tgep24ng [ , 1 ] , tgep24 [ , 2 ] , l a b e l s=colnames ( gep24 ) , cex =0.4)
30
31 p lo t ( tvp6 , pch=20, c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1 " , ylab=" P r o j e c t i o n 2
" , main="TSNE of VIPER P r o f i l e s , 6hr " )
32 t ex t ( tvp6 [ , 1 ] , tvp6 [ , 2 ] , l a b e l s=colnames ( vp6 ) , cex =0.4)
33
34 p lo t ( tvp24 , pch=20, c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1 " , ylab=" P r o j e c t i o n
2 " , main="TSNE of VIPER P r o f i l e s , 24 hr " )
35 t ex t ( tvp24 [ , 1 ] , tvp24 [ , 2 ] , l a b e l s=colnames ( vp24 ) , cex =0.4)
36
37 dev . o f f ( )
38
39 #########################
40 # S i n g l e p l a t e a n a l y s i s
41 gPlate1_6 <− s1 [ , c ( 1 : 9 2 ) ]
42 gPlate1_6 <− gPlate1_6 [ , order ( colnames ( gPlate1_6) ) ]
43 gPlate1_24 <− s1 [ , c ( 9 3 : 1 8 4 ) ]
44 gPlate1_24 <− gPlate1_2 4 [ , order ( colnames ( gPlate1_24) ) ]
45
46 vPlate1_6 <− vp1 [ , c ( 1 : 9 2 ) ]
47 vPlate1_6 <− vPlate1_6 [ , order ( colnames ( vPlate1_6) ) ]
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48 vPlate1_24 <− vp1 [ , c ( 9 3 : 1 8 4 ) ]
49 vPlate1_24 <− vPlate1_2 4 [ , order ( colnames ( vPlate1_24) ) ]
50
51 t p l a t e 1_6 <− t sne ( t ( gPlate1_6) )
52 t p l a t e 1_24 <− t sne ( t ( gPlate1_24) )
53 t v i p e r 1_6 <− t sne ( t ( vPlate1_6) )
54 t v i p e r 1_24 <− t sne ( t ( vPlate1_24) )
55
56 pdf ( " bt20_tsne_s i n g l e P l a t e_a l lSamples_withLabels . pdf " , h=20, w=20, p o i n t s i z e
=18)
57 par ( mfrow=c (2 , 2 ) )
58 p lo t ( t p l a t e 1_6 , pch = seq (1 ,23 , by=2) , c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1 "
, ylab=" P r o j e c t i o n 2 " , main="TSNE of Gene Express ion P r o f i l e s , 6hr " )
59 # text ( t p l a t e 1_6 [ , 1 ] , t p l a t e 1_6 [ , 2 ] , l a b e l s=colnames ( gPlate1_6) , cex =0.4)
60
61 p lo t ( t p l a t e 1_24 , pch = seq (1 ,23 , by=2) , c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1
" , ylab=" P r o j e c t i o n 2 " , main="TSNE of Gene Express ion P r o f i l e s , 24 hr " )
62 # text ( t p l a t e 1_2 4 [ , 1 ] , t p l a t e 1_2 4 [ , 2 ] , l a b e l s=colnames ( gPlate1_24) , cex =0.4)
63
64 p lo t ( t v i p e r 1_6 , pch = seq (1 ,23 , by=2) , c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1 "
, ylab=" P r o j e c t i o n 2 " , main="TSNE of VIPER P r o f i l e s , 6hr " )
65 # text ( t v i p e r 1_6 [ , 1 ] , t v i p e r 1_6 [ , 2 ] , l a b e l s=colnames ( vPlate1_6) , cex =0.4)
66
67 p lo t ( t v i p e r 1_24 , pch = seq (1 ,23 , by=2) , c o l=rgb ( 0 , 0 , 0 , 0 . 5 ) , x lab=" P r o j e c t i o n 1
" , ylab=" P r o j e c t i o n 2 " , main="TSNE of VIPER P r o f i l e s , 24 hr " )
68 # text ( t v i p e r 1_2 4 [ , 1 ] , t v i p e r 1_2 4 [ , 2 ] , l a b e l s=colnames ( vPlate1_24) , cex =0.4)
69
70 dev . o f f ( )
Algorithm 6.2: Computing t-SNE and plotting the results.
C.3 Calculating Gene Expression and VIPER Activity Signatures
1
2 setwd ( " ~/ P r o j e c t s /PLATE−Seq/exo/Expt2_exoPlusOnly /norm2All/ " )
3 packages <− c ( " v ipe r " , " a t o o l s " , " aanot " , "DESeq" , " limma " , " dplyr " , "DeMAND" ,
" g p l o t s " )
4 sapply ( packages , r equ i r e , cha rac t e r . only = TRUE, q u i e t l y = TRUE)
5 rm( packages )
6 source ( " ~/ P r o j e c t s /PLATE−Seq/exo/Expt2_exoPlusOnly /normToDMSO/ v i p e r S i m i l a r i t y 2
.R" )
7
8 load ( " . . /TruSeq/ PeterCounts / t ruseq_rawCounts_Peter . rda " ) # truseq RAW
counts
9 load ( " . . /deExoRepeat . RData" ) # p l a t e s e q DE−
s t a b i l i z e d counts
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10
11 deTS <− DEtransform ( truseqRaw )
12 rm( truseqRaw )
13
14 # Check the c o r r e l a t i o n s between treatments
15 t sne (deTS [ 1 : 1 0 0 0 , ] )
16
17 # dePlus <− dePlus [ , −grep ( "_1\$ " , colnames ( dePlus ) ) ]
18 dePlus <− dePlus [ , − which ( colnames ( dePlus )=="DMSO_5 " ) ]
19 pcp lot ( dePlus )
20 ### Computing s i g n a t u r e s r e l a t i v e to DMSO f o r each sample #######
21 #a s s i g n columns l a b e l e d "DMSO" as c t r l
22 tx <− t ( sapply ( s t r s p l i t ( colnames ( dePlus ) , "_" ) , f unc t i on ( x ) x ) )
23 c t r l <− dePlus [ , tx [ ,1]== "DMSO" ]
24
25 # Create a matrix ho ld ing only treatment samples
26 t r e a t <− dePlus [ , tx [ , 1 ] !="DMSO" ]
27
28 # Repeat above s t e p s f o r TruSeq l i b r a r y
29 tx2 <− t ( sapply ( s t r s p l i t ( colnames (deTS) , "_" ) , f unc t i on ( x ) x ) )
30 c t r l 2 <− deTS [ , tx2 [ ,1]== "DMSO" ]
31
32 # Create a matrix ho ld ing only treatment samples
33 t r ea t30 <− deTS [ , tx2 [ , 1 ] !="DMSO" ]
34
35 # Normalize GES f o r each r e p l i c a t e aga in s t a l l o the r s
36 tsCmpAll <− t ( s c a l e ( t ( t r ea t30 ) ) ) # s u b t r a c t s the mean o f each row and d i v i d e s
by the standard d e v i a t i o n o f each row
37 colnames ( tsCmpAll ) <− paste ( " TruSeq " , colnames ( tsCmpAll ) , sep = "_" )
38 save ( tsCmpAll , f i l e="GES_norm2All_TruSeq . rda " )
39 psCmpAll <− t ( s c a l e ( t ( t r e a t ) ) )
40 colnames ( psCmpAll ) <− paste ( "PLATESeq" , colnames ( psCmpAll ) , sep = "_" )
41 save ( psCmpAll , f i l e="GES_norm2All_PLATESEQ. rda " )
42
43 # Sort e x p r e s s i o n matr i ce s by treatment name & combine matr i ce s
44 psCmpAll <− psCmpAll [ , s o r t ( colnames ( psCmpAll ) ) ]
45 tsCmpAll <− tsCmpAll [ , s o r t ( colnames ( tsCmpAll ) ) ]
46 genes <− i n t e r s e c t ( rownames ( psCmpAll ) , rownames ( tsCmpAll ) )
47 gepcmp <− cbind ( psCmpAll [ match ( genes , rownames ( psCmpAll ) ) , ] , tsCmpAll [ match (
genes , rownames ( tsCmpAll ) ) , ] )
48
49 # Test treatment r e p l i c a t e s i m i l a r i t i e s
50 dd1 <− v i p e r S i m i l a r i t y ( gepcmp , nn=50, method=" two . s ided " )
51 par (mar=c (1 , 10 , 12 , 1) + 0 . 1 )
52 diag ( dd1 ) <− NA
53 plothm ( dd1 , g r id=F)
54 a x i s (3 , 1 : nco l ( gepcmp ) , colnames ( gepcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex .
a x i s =0.7)
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55 a x i s (2 , nco l ( gepcmp ) : 1 , colnames ( gepcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex .
a x i s =0.7)
56 t i t l e ( main="A. GEP S i m i l a r i t y Between Treatment R e p l i c a t e s " , l i n e =10, cex . main
=2)
57
58 # Plot PLATE−Seq samples aga in s t TruSeq samples by gene e x p r e s s i o n (84 x14 )
59 # vsm <− dd1 [ 1 : 7 7 , ] [ , − c ( 1 : 7 7 ) ]
60 vsm <− dd1 [ 1 : 8 4 , ] [ , − c ( 1 : 8 4 ) ]
61 par (mar=c (1 , 10 , 12 , 1) + 0 . 1 )
62 plothm (vsm , g r id=F)
63 # r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (67 ,56 ,45 ,34 ,23 , 12 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (77 ,66 ,55 ,44 ,33 ,22 ,11 ) +0.5 , lwd=5)
64 r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (73 ,61 ,49 ,37 ,25 , 13 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (84 ,72 ,60 ,48 ,36 ,24 ,12 ) +0.5 , lwd=5)
65 a x i s (3 , 1 : nco l (vsm) , colnames (vsm) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s =0.7)
66 a x i s (2 , nrow (vsm) : 1 , rownames (vsm) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s =0.7)




70 # BRCA TCGA regu lon
71 load ( " ~/ P r o j e c t s /PLATE−Seq/ Interactomes /brca−tcga−t f −regu lon . rda " )
72 reg <− r e g u l
73 rm( reg )
74
75 vps <− v ipe r ( psCmpAll , regu l , method=" none " )
76 save ( vps , f i l e=" viperRes_norm2All_PLATESEQ. rda " )
77
78 vts <− v ipe r ( tsCmpAll , regu l , method=" none " )
79 save ( vts , f i l e=" viperRes_norm2All_TruSeq . rda " )
80
81 t f s <− i n t e r s e c t ( rownames ( vps ) , rownames ( vts ) )
82 tfcmp <− cbind ( vps [ match ( t f s , rownames ( vps ) ) , ] , v t s [ match ( t f s , rownames ( vts ) )
, ] )
83
84 # Plot PLATE−Seq samples aga in s t TruSeq samples by VIPER a c t i v i t y (84 x14 )
85 dd2 <− s c a l e ( v i p e r S i m i l a r i t y 2 ( tfcmp , nn=0.01 , method=" two . s ided " ) ) # va lues
in t h i s p l o t have to be s c a l e d because o f the l a r g e d i f f e r e n c e in NES
between TruSeq & PLATE−Seq , stemming from the d i f f e r e n t gene s e t s i z e s
86 par (mar=c (1 , 10 , 12 , 1) + 0 . 1 )
87 diag ( dd2 ) <− NA
88 plothm ( dd2 , g r id=F)
89 a x i s (3 , 1 : nco l ( tfcmp ) , colnames ( tfcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
90 a x i s (2 , nco l ( tfcmp ) : 1 , colnames ( tfcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)




93 # Plot PLATE−Seq samples aga in s t TruSeq samples on a tx−tx− b a s i s (12 x2 )
94 vsm2 <− dd2 [ 1 : 8 4 , ] [ , − c ( 1 : 8 4 ) ]
95 par (mar=c (1 , 10 , 12 , 1) + 0 . 1 )
96 plothm (vsm2 , g r id=F)
97 r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (73 ,61 ,49 ,37 ,25 , 13 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (84 ,72 ,60 ,48 ,36 ,24 ,12 ) +0.5 , lwd=5)
98 # r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (67 ,56 ,45 ,34 ,23 , 12 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (77 ,66 ,55 ,44 ,33 ,22 ,11 ) +0.5 , lwd=5)
99 a x i s (3 , 1 : nco l (vsm2) , colnames (vsm2) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
100 a x i s (2 , nrow (vsm2) : 1 , rownames (vsm2) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)




104 # Plot bloody everyth ing toge the r
105 pdf ( " Comparatron_outl iersRemoved_norm2All_BRCA_TFonly . pdf " , w=32, h=32,
p o i n t s i z e =20)
106 par ( mfrow=c (2 , 2 ) )
107 par (mar=c (1 , 10 , 12 , 1) + 0 . 1 )
108 plothm ( dd1 , g r id=F)
109 a x i s (3 , 1 : nco l ( gepcmp ) , colnames ( gepcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex .
a x i s =0.7)
110 a x i s (2 , nco l ( gepcmp ) : 1 , colnames ( gepcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex .
a x i s =0.7)
111 t i t l e ( main="A. GEP S i m i l a r i t y Between Treatment R e p l i c a t e s " , l i n e =10, cex . main
=2)
112
113 plothm (vsm , g r id=F)
114 r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (73 ,61 ,49 ,37 ,25 , 13 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (84 ,72 ,60 ,48 ,36 ,24 ,12 ) +0.5 , lwd=5)
115 a x i s (3 , 1 : nco l (vsm) , colnames (vsm) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s =0.7)
116 a x i s (2 , nrow (vsm) : 1 , rownames (vsm) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s =0.7)
117 t i t l e ( main="B. GEP S i m i l a r i t y Between Library Preparat ion Methods " , l i n e =10,
cex . main=2)
118
119 plothm ( dd2 , g r id=F)
120 a x i s (3 , 1 : nco l ( tfcmp ) , colnames ( tfcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
121 a x i s (2 , nco l ( tfcmp ) : 1 , colnames ( tfcmp ) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
122 t i t l e ( main="C. VIPER S i m i l a r i t y Between Treatment R e p l i c a t e s " , l i n e =10, cex .
main=2)
123
124 plothm (vsm2 , g r id=F)
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125 r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (73 ,61 ,49 ,37 ,25 , 13 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (84 ,72 ,60 ,48 ,36 ,24 ,12 ) +0.5 , lwd=5)
126 a x i s (3 , 1 : nco l (vsm2) , colnames (vsm2) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
127 a x i s (2 , nrow (vsm2) : 1 , rownames (vsm2) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
128 t i t l e ( main="D. VIPER S i m i l a r i t y Between Library Preparat ion Methods " , l i n e =10,
cex . main=2)
129 dev . o f f ( )
130
131 # Plot the two 12x84 graphs toge the r
132 pdf ( "PSvsTS_norm2All_BRCA_TFonly . pdf " , w=32, h=16, p o i n t s i z e =20)
133 par ( mfrow=c (1 , 2 ) )
134 par (mar=c (1 , 10 , 12 , 1) + 0 . 1 )
135 plothm (vsm , g r id=F)
136 r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (73 ,61 ,49 ,37 ,25 , 13 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (84 ,72 ,60 ,48 ,36 ,24 ,12 ) +0.5 , lwd=5)
137 a x i s (3 , 1 : nco l (vsm) , colnames (vsm) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s =0.7)
138 a x i s (2 , nrow (vsm) : 1 , rownames (vsm) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s =0.7)
139 t i t l e ( main="A. GEP S i m i l a r i t y Between Library Preparat ion Methods " , l i n e =10,
cex . main=1)
140
141 plothm (vsm2 , g r id=F)
142 r e c t ( c (1 , 3 , 5 , 7 , 9 , 11 , 13 ) −0.5 , c (73 ,61 ,49 ,37 ,25 , 13 ,1 ) −0.5 , c (2 , 4 , 6 , 8 , 10 , 12 , 14 )
+0.5 , c (84 ,72 ,60 ,48 ,36 ,24 ,12 ) +0.5 , lwd=5)
143 a x i s (3 , 1 : nco l (vsm2) , colnames (vsm2) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
144 a x i s (2 , nrow (vsm2) : 1 , rownames (vsm2) , t i c k=FALSE, l i n e =−.5, l a s =2, cex . a x i s
=0.7)
145 t i t l e ( main="B. VIPER S i m i l a r i t y Between Library Preparat ion Methods " , l i n e =10,
cex . main=1)
146 dev . o f f ( )
Algorithm 6.3: Calculating Gene Expression and VIPER Activity Signatures.
C.4 DESeq Normalization and Clustering by MDS
1 # DGE by DESeq2 f o r TruSeq counts2
2 setwd ( " ~/ P r o j e c t s /PLATE−Seq/exo/ Ana lys i s / " )
3 l i b r a r y (DESeq2)
4
5 # Step 1 : D i f f e r e n t i a l Gene Express ion us ing DESeq2
6 # load ( " ~/ P r o j e c t s /PLATE−Seq/exo/Expt2_exoPlusOnly /TruSeq/ Petercounts2 / t ruseq_
rawcounts2_Peter . rda " )
7 counts2 <− read . t a b l e ( " ~/ P r o j e c t s /PLATE−Seq/exo/Expt2_exoPlusOnly /TruSeq/
Petercounts /FR_truseq . c t s . txt " , sep=" \ t " , header=T)
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8 rownames ( counts2 ) <− counts2 [ , 1 ]
9 counts2 <− counts2 [ , −1]
10
11 colnames ( counts2 ) <− c ( " Mitoxantrone_1 " , " Mitoxantrone_2 " , " C r i z o t i n i b_1 " , "
C r i z o t i n i b_2 " ,
12 " Albendazole_1 " , " Albendazole_2 " , " I d a r u b i c i n_1 " , "
I d a r u b i c i n_2 " ,
13 " Aprepitant_1 " , " Aprepitant_2 " , " Gemcitabine_1 " , "
Gemcitabine_2 " ,
14 " Bortezomib_1 " , " Bortezomib_2 " , "DMSO_1 " , "DMSO_2 " )
15
16 # order columns by tx name
17 counts2 <− counts2 [ , order ( colnames ( counts2 ) ) ]
18
19 # reorde r columns to group by treatment & c o n t r o l
20 counts2 <− counts2 [ , c ( 1 : 8 , 1 1 : 1 6 , 9 , 1 0 ) ]
21
22 # Convert to matrix
23 counts2 <− as . matrix ( counts2 )
24 counts2 [ 1 : 2 , ]
25
26 # remove rows conta in ing only z e r o s
27 counts2 <− counts2 [ ! ! rowSums( abs ( counts2 ) ) , ]
28 save ( counts2 , f i l e=" t ruseq_rawCounts_sor t ed . rda " )
29
30 tx <− t ( sapply ( s t r s p l i t ( colnames ( counts2 ) , "_" ) , f unc t i on ( x ) x ) )
31 dmso <− counts2 [ , tx [ ,1]== "DMSO" ]
32 alben <− counts2 [ , tx [ ,1]== " Albendazole " ]
33 alben <− cbind (dmso , a lben )
34 ( cond i t i on1 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " Albendazole " , 2) ) ) )
35
36 aprep <− counts2 [ , tx [ ,1]== " Aprepitant " ]
37 aprep <− cbind (dmso , aprep )
38 ( cond i t i on2 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " Aprepitant " , 2) ) ) )
39
40 bort <− counts2 [ , tx [ ,1]== " Bortezomib " ]
41 bort <− cbind (dmso , bort )
42 ( cond i t i on3 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " Bortezomib " , 2) ) ) )
43
44 c r i z <− counts2 [ , tx [ ,1]== " C r i z o t i n i b " ]
45 c r i z <− cbind (dmso , c r i z )
46 ( cond i t i on4 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " C r i z o t i n i b " , 2) ) ) )
47
48 gem <− counts2 [ , tx [ ,1]== " Gemcitabine " ]
49 gem <− cbind (dmso , gem)
50 ( cond i t i on5 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " Gemcitabine " , 2) ) ) )
51
52 ida <− counts2 [ , tx [ ,1]== " I d a r u b i c i n " ]
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53 ida <− cbind (dmso , ida )
54 ( cond i t i on6 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " I d a r u b i c i n " , 2) ) ) )
55
56 mito <− counts2 [ , tx [ ,1]== " Mitoxantrone " ]
57 mito <− cbind (dmso , mito )
58 ( cond i t i on7 <− f a c t o r ( c ( rep ( "DMSO" , 2) , rep ( " Mitoxantrone " , 2) ) ) )
59
60 # Analys i s with DESeq2 −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
61
62 # Create a co ldata frame and i n s t a n t i a t e the DESeqDataSet . See ?
DESeqDataSetFromMatrix
63 ( co ldata1 <− data . frame ( row . names=colnames ( a lben ) , cond i t i on1 ) )
64 ( co ldata2 <− data . frame ( row . names=colnames ( aprep ) , cond i t i on2 ) )
65 ( co ldata3 <− data . frame ( row . names=colnames ( bort ) , cond i t i on3 ) )
66 ( co ldata4 <− data . frame ( row . names=colnames ( c r i z ) , cond i t i on4 ) )
67 ( co ldata5 <− data . frame ( row . names=colnames (gem) , cond i t i on5 ) )
68 ( co ldata6 <− data . frame ( row . names=colnames ( ida ) , cond i t i on6 ) )
69 ( co ldata7 <− data . frame ( row . names=colnames ( mito ) , cond i t i on7 ) )
70
71 dds2_1 <− DESeqDataSetFromMatrix ( countData=alben , colData=coldata1 , des ign=~
cond i t i on1 )
72 dds2_2 <− DESeqDataSetFromMatrix ( countData=aprep , colData=coldata2 , des ign=~
cond i t i on2 )
73 dds2_3 <− DESeqDataSetFromMatrix ( countData=bort , colData=coldata3 , des ign=~
cond i t i on3 )
74 dds2_4 <− DESeqDataSetFromMatrix ( countData=c r i z , colData=coldata4 , des ign=~
cond i t i on4 )
75 dds2_5 <− DESeqDataSetFromMatrix ( countData=gem , colData=coldata5 , des ign=~
cond i t i on5 )
76 dds2_6 <− DESeqDataSetFromMatrix ( countData=ida , colData=coldata6 , des ign=~
cond i t i on6 )
77 dds2_7 <− DESeqDataSetFromMatrix ( countData=mito , colData=coldata7 , des ign=~




81 # Run DESeq
82 dds2_1 <− DESeq( dds2_1)
83 dds2_2 <− DESeq( dds2_2)
84 dds2_3 <− DESeq( dds2_3)
85 dds2_4 <− DESeq( dds2_4)
86 dds2_5 <− DESeq( dds2_5)
87 dds2_6 <− DESeq( dds2_6)
88 dds2_7 <− DESeq( dds2_7)
89
90 mcl i s ty <− l i s t ( dds2_1 , dds2_2 , dds2_3 , dds2_4 , dds2_5 , dds2_6 , dds2_7)
91
92 r e s L i s t <− l i s t ( )
98
93 f o r ( i in 1 : 7 ) {
94 r e s1 <− r e s u l t s ( mc l i s ty [ [ i ] ] )
95 t a b l e ( r e s1 $padj <0.05)
96 r e s1 <− r e s1 [ order ( r e s1 $ padj ) , ]
97 tmpdat <− merge ( as . data . frame ( r e s1 ) , as . data . frame ( counts ( mc l i s ty [ [ i ] ] ,
normal ized=TRUE) ) , by=" row . names " , s o r t=FALSE)
98 names ( tmpdat ) [ 1 ] <− " Gene "
99 tmp <− tmpdat [ , 1 0 : 1 1 ]
100 rownames (tmp) <− tmpdat [ , 1 ]
101 r e s L i s t [ [ l ength ( r e s L i s t ) +1] ] <− tmp
102 }
103
104 f o r ( i in 1 : 7 ) {
105 r e s L i s t [ [ i ] ] <− r e s L i s t [ [ i ] ] [ rownames ( r e s L i s t [ [ 1 ] ] ) , ] # orde r s l i s t
e lements by gene orde r ing o f the f i r s t t a b l e
106 }
107
108 d i f fGene s <− do . c a l l ( cbind , r e s L i s t )
109 save ( d i f fGenes , f i l e="DEG_TruSeq . rda " )
110
111 ##############################################################
112 # Repeat that whole goddam thing f o r PLATE−Seq
113 counts <− read . t a b l e ( " PF003_R2 . c t s . txt " )
114 rownames ( counts ) <− counts [ , 1 ]
115 counts <− counts [ , −1]
116
117 # Apply treatment names to columns
118 tmp <− readLines ( " exoSamples . txt " ) #samples are l i s t e d column−wise
119 colnames ( counts ) <− tmp
120 colnames ( counts ) <− paste0 ( colnames ( counts ) , "_" , rep ( 1 : 1 2 , each=8) )
121
122 # Remove DMSO_5
123 counts <− counts [ , −40]
124
125 # Remove ERCC rows
126 counts <− counts [− grep ( "ERCC−" , rownames ( counts ) ) , ]
127
128 # order columns by tx name
129 counts <− counts [ , order ( colnames ( counts ) ) ]
130 counts <− counts [ , c ( 1 : 4 8 , 6 0 : 9 5 , 4 9 : 5 9 ) ]
131
132 # Convert to matrix
133 counts <− as . matrix ( counts )
134 head ( counts )
135 save ( counts , f i l e=" plateseqRawCounts . rda " )
136
137 tx <− t ( sapply ( s t r s p l i t ( colnames ( counts ) , "_" ) , f unc t i on ( x ) x ) )
138 dmso <− counts [ , tx [ ,1]== "DMSO" ]
99
139 alben <− counts [ , tx [ ,1]== " Albendazole " ]
140 alben <− cbind (dmso , a lben )
141 ( cond i t i on1 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " Albendazole " , 12) ) ) )
142
143 aprep <− counts [ , tx [ ,1]== " Aprepitant " ]
144 aprep <− cbind (dmso , aprep )
145 ( cond i t i on2 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " Aprepitant " , 12) ) ) )
146
147 bort <− counts [ , tx [ ,1]== " Bortezomib " ]
148 bort <− cbind (dmso , bort )
149 ( cond i t i on3 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " Bortezomib " , 12) ) ) )
150
151 c r i z <− counts [ , tx [ ,1]== " C r i z o t i n i b " ]
152 c r i z <− cbind (dmso , c r i z )
153 ( cond i t i on4 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " C r i z o t i n i b " , 12) ) ) )
154
155 gem <− counts [ , tx [ ,1]== " Gemcitabine " ]
156 gem <− cbind (dmso , gem)
157 ( cond i t i on5 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " Gemcitabine " , 12) ) ) )
158
159 ida <− counts [ , tx [ ,1]== " I d a r u b i c i n " ]
160 ida <− cbind (dmso , ida )
161 ( cond i t i on6 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " I d a r u b i c i n " , 12) ) ) )
162
163 mito <− counts [ , tx [ ,1]== " Mitoxantrone " ]
164 mito <− cbind (dmso , mito )
165 ( cond i t i on7 <− f a c t o r ( c ( rep ( "DMSO" , 11) , rep ( " Mitoxantrone " , 12) ) ) )
166
167 # Analys i s with DESeq2 −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
168 # Create a co ldata frame and i n s t a n t i a t e the DESeqDataSet . See ?
DESeqDataSetFromMatrix
169 ( co ldata1 <− data . frame ( row . names=colnames ( a lben ) , cond i t i on1 ) )
170 ( co ldata2 <− data . frame ( row . names=colnames ( aprep ) , cond i t i on2 ) )
171 ( co ldata3 <− data . frame ( row . names=colnames ( bort ) , cond i t i on3 ) )
172 ( co ldata4 <− data . frame ( row . names=colnames ( c r i z ) , cond i t i on4 ) )
173 ( co ldata5 <− data . frame ( row . names=colnames (gem) , cond i t i on5 ) )
174 ( co ldata6 <− data . frame ( row . names=colnames ( ida ) , cond i t i on6 ) )
175 ( co ldata7 <− data . frame ( row . names=colnames ( mito ) , cond i t i on7 ) )
176
177 dds_1 <− DESeqDataSetFromMatrix ( countData=alben , colData=coldata1 , des ign=~
cond i t i on1 )
178 dds_2 <− DESeqDataSetFromMatrix ( countData=aprep , colData=coldata2 , des ign=~
cond i t i on2 )
179 dds_3 <− DESeqDataSetFromMatrix ( countData=bort , colData=coldata3 , des ign=~
cond i t i on3 )
180 dds_4 <− DESeqDataSetFromMatrix ( countData=c r i z , colData=coldata4 , des ign=~
cond i t i on4 )
100
181 dds_5 <− DESeqDataSetFromMatrix ( countData=gem , colData=coldata5 , des ign=~
cond i t i on5 )
182 dds_6 <− DESeqDataSetFromMatrix ( countData=ida , colData=coldata6 , des ign=~
cond i t i on6 )
183 dds_7 <− DESeqDataSetFromMatrix ( countData=mito , colData=coldata7 , des ign=~
cond i t i on7 )
184
185 # Run DESeq
186 dds_1 <− DESeq( dds_1)
187 dds_2 <− DESeq( dds_2)
188 dds_3 <− DESeq( dds_3)
189 dds_4 <− DESeq( dds_4)
190 dds_5 <− DESeq( dds_5)
191 dds_6 <− DESeq( dds_6)
192 dds_7 <− DESeq( dds_7)
193 # The problem now i s that the re are a l o t o f NAs in the r e s u l t i n g DESeq
o b l e c t s
194 mcl i s ty <− l i s t ( dds_1 , dds_2 , dds_3 , dds_4 , dds_5 , dds_6 , dds_7)
195
196 # Check d i f f e r e n t i a l e x p r e s s i o n r e s u l t s ( s a n i ty check )
197 tmp <− r e s u l t s ( dds_2)
198 t a b l e (tmp$padj <0.05)
199 ## Order by adjusted p−value
200 tmp <− tmp [ order (tmp$ padj ) , ]
201 ## Merge with normal ized count data
202 tmpdata <− merge ( as . data . frame (tmp) , as . data . frame ( counts ( dds_2 , normal ized=
TRUE) ) , by=" row . names " , s o r t=FALSE)
203 names ( tmpdata ) [ 1 ] <− " Gene "
204 head ( tmpdata )
205
206 r e s L i s t <− l i s t ( )
207 f o r ( i in 1 : 7 ) {
208 r e s1 <− r e s u l t s ( mc l i s ty [ [ i ] ] )
209 t a b l e ( r e s1 $padj <0.05)
210 r e s1 <− r e s1 [ order ( r e s1 $ padj ) , ]
211 tmpdat <− merge ( as . data . frame ( r e s1 ) , as . data . frame ( counts ( mc l i s ty [ [ i ] ] ,
normal ized=TRUE) ) , by=" row . names " , s o r t=FALSE)
212 names ( tmpdat ) [ 1 ] <− " Gene "
213 tmp <− tmpdat [ , 1 9 : 3 0 ]
214 rownames (tmp) <− tmpdat [ , 1 ]
215 r e s L i s t [ [ l ength ( r e s L i s t ) +1] ] <− tmp
216 }
217
218 f o r ( i in 1 : 7 ) {
219 r e s L i s t [ [ i ] ] <− r e s L i s t [ [ i ] ] [ rownames ( r e s L i s t [ [ 1 ] ] ) , ] # orde r s l i s t




222 d i f fGene s_ps <− do . c a l l ( cbind , r e s L i s t )
223 save ( d i f fGene s_ps , f i l e="DEG_p l a t e s e q . rda " )
224
225 # Alternate method : a s s i g n DEG by log2 f o l d change > 2
226 l f c L i s t <− l i s t ( )
227 f o r ( i in 1 : 7 ) {
228 r e s1 <− r e s u l t s ( mc l i s ty [ [ i ] ] )
229 t a b l e ( abs ( r e s1 $ log2FoldChange ) > 2)
230 r e s1 <− r e s1 [ order ( r e s1 $ padj ) , ]
231 tmpdat <− merge ( as . data . frame ( r e s1 ) , as . data . frame ( counts ( mc l i s ty [ [ i ] ] ,
normal ized=TRUE) ) , by=" row . names " , s o r t=FALSE)
232 names ( tmpdat ) [ 1 ] <− " Gene "
233 tmp <− tmpdat [ , 1 9 : 3 0 ]
234 rownames (tmp) <− tmpdat [ , 1 ]
235 l f c L i s t [ [ l ength ( l f c L i s t ) +1] ] <− tmp
236 }
237
238 f o r ( i in 1 : 7 ) {
239 l f c L i s t [ [ i ] ] <− l f c L i s t [ [ i ] ] [ rownames ( l f c L i s t [ [ 1 ] ] ) , ] # orde r s l i s t
e lements by gene orde r ing o f the f i r s t t a b l e
240 }
241
242 diffGenByLFC_ps <− do . c a l l ( cbind , l f c L i s t )
243 save ( diffGenByLFC_ps , f i l e="DEG_byLFC_p l a t e s e q . rda " )
244
245 ##############################################################
246 # Compute Eucl idean d i s t a n c e s between columns
247 # PLATE−Seq
248 sampleDists <− as . matrix ( d i s t ( t ( d i f fGene s_ps ) ) )
249
250 # TruSeq
251 sampleDists2 <− as . matrix ( d i s t ( t ( d i f fGene s ) ) )
252
253 # Plot MDS
254 l i b r a r y ( RColorBrewer )
255 l i b r a r y ( limma )
256 # Assign cond i t i on
257 ( cond i t i on <− f a c t o r ( c ( rep ( " Albendazole " , 12) , rep ( " Aprepitant " , 12) , rep ( "
Bortezomib " , 12) ,
258 rep ( " C r i z o t i n i b " , 12) , rep ( " Gemcitabine " , 12) , rep ( "
I d a r u b i c i n " , 12) ,
259 rep ( " Mitoxantrone " , 12) ) ) )
260
261 ( cond i t i on2 <− f a c t o r ( c ( rep ( " Albendazole " , 2) , rep ( " Aprepitant " , 2) , rep ( "
Bortezomib " , 2) ,
262 rep ( " C r i z o t i n i b " , 2) , rep ( " Gemcitabine " , 2) , rep ( "
I d a r u b i c i n " , 2) ,
263 rep ( " Mitoxantrone " , 2) ) ) )
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264
265 ( mycols <− brewer . pa l (7 , " Dark2 " ) [ 1 : l ength ( unique ( cond i t i on ) ) ] )
266 ( mycols2 <− brewer . pa l (7 , " Dark2 " ) [ 1 : l ength ( unique ( cond i t i on2 ) ) ] )
267
268 p1<−plotMDS( as . matrix ( sampleDists ) , top =500 , pch=20, c o l=mycols [ c ond i t i on ] )
269 p2<−plotMDS( as . matrix ( sampleDists2 ) , top =500 , pch=0, c o l=mycols2 [ cond i t i on2 ] )
270
271
272 pdf ( "mds_plateseqVStruseq . pdf " , h=6, w=5, p o i n t s i z e =12)
273 p lo t ( p2$x , p2$y , pch=0, c o l=mycols2 [ cond i t i on2 ] , main="MDS of D i f f e r e n t i a l Gene
Express ion " )
274 po in t s ( p1$x , p1$y , pch=20, c o l=mycols [ c ond i t i on ] )
275 dev . o f f ( )
276
277 #############################################################
278 # VIPER a n a l y s i s o f DESeq−analyzed DEGs
279 setwd ( " ~/ P r o j e c t s /PLATE−Seq/exo/ Ana lys i s / " )
280 l i b r a r y ( v ipe r )
281 l i b r a r y ( aanot )
282 data ( desc )
283
284 load ( " ~/ P r o j e c t s /PLATE−Seq/ Interactomes /brca−tcga−t f −regu lon . rda " )
285 reg <− r e g u l
286 rm( reg )
287
288 # NB: the d i f fGene s o b j e c t s were poor ly named − they are NORMALIZED, but not
n e c e s s a r i l y d i f f e r e n t i a l l y expres sed . FML.
289 # PLATE−Seq
290 tmp <− gene2entrez ( rownames ( d i f fGene s_ps ) )
291
292 unique_i n d i c e s <− which ( ! dup l i ca t ed (tmp) & ! i s . na (tmp) )
293
294 tmp_unique <− tmp [ unique_i n d i c e s ]
295 d i f fGene s_ps_unique <− d i f fGene s_ps [ unique_i n d i c e s , ]
296 rownames ( d i f fGene s_ps_unique ) <− tmp_unique
297
298 vps <− v ipe r ( d i f fGene s_ps_unique , regu l , method=" none " )
299 save ( vps , f i l e=" viperRes_DESeq_PLATESEQ. rda " )
300
301 # TruSeq
302 tmp <− gene2entrez ( rownames ( d i f fGene s ) )
303
304 unique_i n d i c e s <− which ( ! dup l i ca t ed (tmp) & ! i s . na (tmp) )
305
306 tmp_unique <− tmp [ unique_i n d i c e s ]
307 d i f fGene s_Ts_unique <− d i f fGene s [ unique_i n d i c e s , ]




311 vts <− v ipe r ( d i f fGene s_Ts_unique , regu l , method=" none " )
312 save ( vts , f i l e=" viperRes_DESeq_TruSeq . rda " )
313
314 # Comparison between averaged 30M and p l a t e s e q based on gene e x p r e s s i o n
s i g n a t u r e s
315 genes <− i n t e r s e c t ( rownames ( vps ) , rownames ( vts ) )
316 vps <− vps [ match ( genes , rownames ( vps ) ) , ]
317 vts <− vts [ match ( genes , rownames ( vts ) ) , ]
318
319 # Compute Eucl idean d i s t a n c e s between columns
320 # PLATE−Seq
321 sampleDists <− as . matrix ( d i s t ( t ( vps ) ) )
322
323 # TruSeq
324 sampleDists2 <− as . matrix ( d i s t ( t ( vts ) ) )
325
326 # Plot MDS
327 l i b r a r y ( RColorBrewer )
328 l i b r a r y ( limma )
329 # Assign cond i t i on
330 ( cond i t i on <− f a c t o r ( c ( rep ( " Albendazole " , 12) , rep ( " Aprepitant " , 12) , rep ( "
Bortezomib " , 12) ,
331 rep ( " C r i z o t i n i b " , 12) , rep ( " Gemcitabine " , 12) , rep ( "
I d a r u b i c i n " , 12) ,
332 rep ( " Mitoxantrone " , 12) ) ) )
333
334 ( cond i t i on2 <− f a c t o r ( c ( rep ( " Albendazole " , 2) , rep ( " Aprepitant " , 2) , rep ( "
Bortezomib " , 2) ,
335 rep ( " C r i z o t i n i b " , 2) , rep ( " Gemcitabine " , 2) , rep ( "
I d a r u b i c i n " , 2) ,
336 rep ( " Mitoxantrone " , 2) ) ) )
337
338 ( mycols <− brewer . pa l (7 , " Dark2 " ) [ 1 : l ength ( unique ( cond i t i on ) ) ] )
339 ( mycols2 <− brewer . pa l (7 , " Dark2 " ) [ 1 : l ength ( unique ( cond i t i on2 ) ) ] )
340
341 p1<−plotMDS( as . matrix ( sampleDists ) , top =500 , pch=20, c o l=mycols [ c ond i t i on ] )
342 p2<−plotMDS( as . matrix ( sampleDists2 ) , top =500 , pch=0, c o l=mycols2 [ cond i t i on2 ] )
343
344
345 pdf ( "mds_VIPER_plateseqVStruseq . pdf " , h=6, w=5, p o i n t s i z e =12)
346 p lo t ( p2$x , p2$y , pch=0, c o l=mycols2 [ cond i t i on2 ] , x lab="MDS Dimension 1 " , ylab="
MDS Dimension 2 " ,
347 main="MDS of VIPER Act iv i ty " )
348 po in t s ( p1$x , p1$y , pch=20, c o l=mycols [ c ond i t i on ] )
349 l egend ( " t o p l e f t " , paste ( c ( " TruSeq " , "PLATE−Seq " ) ) , pch=c (0 , 20) )
350 dev . o f f ( )
Algorithm 6.4: DESeq Normalization and Clustering by MDS.
104
105
